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“Man has gone out to explore other worlds and other civilizations without having explored 
his own labyrinth of dark passages and secret chambers, and without finding what lies be-
hind doorways that he himself has sealed.”  
Stanisław Lem, Solaris
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1. Research summary 
Seasonal Influenza A epidemics account for a higher morbidity than all other respiratory dis-
eases taken together. Influenza viruses can tolerate changes in their antigenic structures, and are 
therefore capable of escaping pre-existing immunity. Such changes also result in a dramatic increase 
of viral resistance to available drugs. Furthermore, influenza vaccines protect only from one or few 
closely related strains, and therefore have to be annually formulated and applied. Thus, a novel, ‘one 
shot’ universal vaccine that provides immunity to wide range of Influenza A strains, including newly 
emerging strains, is highly desirable.  
In my PhD thesis I aimed at defining universal epitopes of hemagglutinin (HA) – the major tar-
get protein for neutralizing antibodies on the Influenza A virus surface. It has been previously shown 
that some individuals possess cross-neutralizing antibodies that bind to more than one of the seven-
teen hemagglutinin subtypes. Crystal structures revealed that these antibodies interact with a hy-
drophobic groove in the HA stem region, and thereby block its pH-dependent conformational change 
necessary for viral-host membrane fusion. Most heterosubtypic monoclonal antibodies (hmAbs) only 
neutralized viruses from one of the two phylogenetic groups. However, two clones capable of neu-
tralizing viruses from both phylogenetic groups have recently been described.  
In this study I extended the knowledge about universal HA epitopes by selecting mAbs capable 
of binding and neutralizing Influenza A subtypes belonging to both groups. To this end, I built phage 
display Fab libraries based on the immune repertoire of a single individual, and these libraries were 
used in a modified selection process. I obtained a set of genetically distinct Fab clones presenting 
different HA cross-reactivity patterns. Two of the most promising candidates were further tested for 
virus-neutralization as IgG1 molecules. Interestingly, one of these clones, referred to as mAb 1.12, 
neutralized a broad spectrum of Influenza A viruses belonging to both phylogenetic groups 1 and 2 
(subtypes H1 to H15), whereas a second clone, mAb 3.1, neutralized several subtypes from phyloge-
netic group 1 (H1, H2, H5, H6). Together with our collaborators we solved the crystal structure of one 
of the complexes to define the recognized conserved HA epitope. Moreover, kinetic and mechanistic 
properties and antiviral mode of action was determined for both clones. I found that neutralization 
of these antibodies is virtually irreversible, that their antiviral activity is not impaired by apically bind-
ing, strain-specific serum antibodies and that they have to bind free virions, as their antiviral activity 
is dramatically reduced once the virus has bound to the cell surface.  
 
Research summary      
 
6 
 
 In a preliminary approach I used the same antigen design that was used in the phage display 
since it was very efficient in selecting heterotypic antibodies. Surprisingly, two subsequent immuniza-
tions of mice with these antigens induced sera cross-reactive to all recombinantly expressed hemag-
glutinins (H1, H2, H3, H4, H5, H7, H12) as evaluated in ELISA. 
 In summary, with the results of this study I show that the development of a universal influenza 
vaccine directed against the conserved epitopes in the stem of the HA protein should be feasible and 
effective, even in the presence of pre-existing strain-specific serum antibodies. 
Zusammenfassung      
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2. Zusammenfassung 
Die jährlichen Influenza A Epidemien sind für eine höhere Morbidität verantwortlich, als alle 
anderen respiratorischen Krankheiten zusammen. Das Influenzavirus ist besitzt die Fähigkeit, 
Änderungen in seiner antigenen Struktur tolerieren zu können und hat daher die Fähigkeit, bereits 
existierender Immunität zu entweichen. Ähnliche Änderungen führen auch zu drastisch erhöhter 
Resistenz gegenüber verwendeten antiviralen Medikamenten. Des weiteren schützen 
Influenzaimpfstoffe nur gegen einzelne oder wenige, eng verwandte Virenstämme und müssen 
deshalb jährlich neu generiert und angewendet werden. Ein Universalimpfstoff, dessen 
immunisierende Wirkung sowohl ein breiteres Spektrum, als auch neu aufkommende Virenstämme 
umfasst, wäre folglich erstrebenswert. 
In dieser Arbeit, erstrebe ich die Erfoschung von Universalepitopen von Hemagglutinin (HA), 
dem Zielprotein für neutralisierende Antikörper auf der Oberfläche der Influenza A Viren. Es wurde 
bereits gezeigt, dass einzelne Individuen neutralisierende Antikörper besitzen, welche mehrere der 
siebzehn Hemagglutinin Subtypen binden können. Kristallstrukturen machen deutlich, dass diese 
Antikörper mit einer hydrophoben Furche der HA Stammregion interagieren und dessen pH-
abhängige Konformationsänderung, welche nötig für die Membranfusion zwischen Virus und 
Wirtshzelle ist, blockieren. Die meisten mhAbs neutralisierten nur Viren, die zu einer der beiden 
phylogenetischen Gruppen gehörten. Kürzlich wurden jedoch zwei Klone beschrieben, welche die 
Fähigkeit besitzen, Viren von beiden phylogenetischen Gruppen zu neutralisieren. 
In dieser Studie habe ich durch Selektieren von Fabs, welche Influenza A Subtypen aus beiden 
phylogenetischen Gruppen binden und neutralisieren können, das Wissen über die Universalepitope 
von HA erweitert. Um dies zu erreichen, generierte ich Phage-Display Fab-Bibliotheken basierend auf 
dem Immunrepertoire von einem einzelnen Individuum, welche dann in einem modifizierten 
Selektionsprozess weiterverwendet wurden. Dadurch erzielte ich einen Satz von genetisch 
unterschiedlichen Fab-Klonen, welche deutliche HA Kreuzreaktivität aufweisen. Zwei der 
meistversprechenden Kandidaten wurden des weiteren auf ihre neutralisierende Wirkung als IgG1 
Moleküle getestet. Interessanterweise konnte einer der Klone, mAb 1.12, die Neutralisation eines 
breiten Spektrums an Influenza A Viren beider Gruppen (Subtypen H1 bis H15) erzielen, während 
dem sich die neutralisierende Wirkung des zweiten Klons, mAb 3.1, auf mehrere Subtypen der 
Gruppe 1 beschränkte (H1, H2, H5, H6). Ermutigt durch diese Resultate, machte ich eine 
Kristallographie Analyse, um das hochkonservierte HA Epitope zu definieren, welches durch mAb 3.1. 
erkannt wird. Darüber hinaus charakterisierte ich kinetische Eigenschaften und die Wirkungsweise 
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der beiden Klone. Ich konnte zeigen, dass die Virus-Neutralisation durch heterosubtypische 
Antikörper praktisch irreversibel ist, dass vorbestehende stammspezifische Serumantikörper keinen 
negativen Einfluss auf diese Antikörper hat, aber auch dass heterosubtypische Antikörper freie Viren 
binden müssen, da sie einen grossen Teil ihrer antiviralen Wirkung einbüssen, nachdem das Virus an 
die Zelle angedockt hat. 
In einer präliminären  Studie verwendete ich das Antigen, das eine sehr hohe Effizienz 
bezüglich der Selektion von heterotypischen Antikörpern im Phage-Display bewiesen hat. Wie die 
Analyse mit ELISA zeigte, resultierten Mausexperimente mit zwei aufeinanderfolgenden 
Immunisierungen mit unserem Antigen in Seren, welche Kreuzreaktivität gegenüber allen getesteten 
rekombinant exprimierten Hemagglutininen (H1, H2, H3, H4, H5, H7, H12) zeigte.  
Mit den Resultaten dieser Studie konnte ich zeigen, dass die Entwicklung eines 
Universalimpfstoffs, der die konservierten Epitope im Stamm vom Influenza HA angreift, möglich sein 
sollte und dass ein solcher Impfstoff auch bei vorbestehenden Stamm-spezifischen Serumantikörpern 
effektiv sein sollte. 
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3. Biology of Influenza A virus 
3.1 Influenza A overview  
Influenza viruses belong to the family Orthomyxoviridae and are divided into 3 genera: A, B and 
C. Influenza A viruses are classified into subtypes based on antigenicity of their surface glycoproteins: 
hemagglutinin (HA) and neuraminidase (NA) [1]. Each Influenza A isolate is named according to the 
virus genus, name of host of origin (besides humans), geographic site of isolation, isolate number, 
year of isolation and HA and NA subtypes in brackets (e.g. A/California/7/2009 (H1N1)). New viruses 
traditionally were classified based on their cross-reactivity with monoclonal antibodies or polyclonal 
sera with specificity to a given subtype. Today, sequencing and phylogenetic analysis is used for the 
classification of influenza viruses. The first Influenza A virus, A/swine/Iowa/30 was isolated by Shope 
in 1930 followed by the isolation of the first human influenza virus by Smith, Andrews and Laidlaw in 
1933 [1]. Since then 17 different HA and 10 different NA subtypes have been reported [2]. 
 Influenza A viruses infect a wide variety of hosts. These include humans, horses, cats, birds, 
dogs, swine, whales and seals [1, 3]. Symptoms and severity of disease depend on species. For in-
stance, in humans fatal infections are common whereas in aquatic birds, the natural reservoir of in-
fluenza A, infection is usually benign or even asymptomatic. The wide host-range of Influenza A can 
be attributed to several features of the virus. First, low requirements for host receptor recognition 
(see chapters 3.3 and 3.5.2.1 for details) [1, 4]. Second, the ability to accommodate extensive chang-
es in surface protein composition in the processes of antigenic drift and shift [3-5]. 
Antigenic drift 
Antigenic drift occurs when point mutations are being accumulated in HA and NA proteins 
leading to the emergence of new antigenic variants due to selection pressure exerted by neutralizing 
antibodies[1] (Figure 1). This process is a result of the lack of proof reading activity of the viral poly-
merase. It is estimated that in case of human viruses, such mutations are fixed at a frequency of less 
than 1% of amino acid composition per year [1]. This frequency is sufficient to enable the virus to 
constantly escape herd immunity, and to be maintained in circulation [1, 6]. Thus antigenic drift is 
the molecular mechanism responsible for seasonal Influenza A outbreaks as new viruses with slightly 
redecorated surface proteins are being generated each year. 
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Figure 1. Antigenic drift of Influenza A virus. The two surface glycoproteins, HA and NA, being the subject of 
antigenic drift are depicted in blue and magenta, respectively. Mutations accumulated during the drift process 
are shown in red (HA) and yellow (NA). Adapted from Lars Hangartner. 
Antigenic shift 
Antigenic shift is a process in which a new HA or NA subtype is being introduced into human vi-
ruses leading to the emergence of a virus variant that is immunologically distinct from previously 
circulating strains [1, 6] (Figure 2). Since there is usually no preexisting immunity to such viruses in 
human population antigenically shifted viruses often cause Influenza A pandemics. A good example 
for antigenic shift is the emergence of pandemic viruses in 1918, 1957, 1968 and 1977 (see chapter 
3.4 for details). Antigenic shift usually occurs when gene segments encoding for HA or NA proteins 
(sometimes with other viral gene segments) are being introduced into the background of human 
viruses. Such reassortment of the genetic information can occur when a cell or organism is simulta-
neously infected with both human and avian viruses, and the resulting virus is a mosaic between 
these two. Reassortment is suspected to primarily occur in swine as they can be infected with both 
avian and human isolates [1]. The new virus can be further transmitted between pigs and humans. 
An alternative way for antigenic shift to occur is direct transmission of avian or swine strain to hu-
mans, followed by adaptation of the virus to the human host. Such zoonotic cases have been well 
documented in the last 50 years [1, 7, 8]. 
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Figure 2. Antigenic shift of Influenza A virus. The exchange of HA (blue to red) and NA (magenta to green) 
between virus subtypes is depicted. Adapted from Lars Hangartner. 
3.2 Structure of the virion 
In electron microscopy, Influenza A virions are present in two forms: spherical with approxi-
mately 100 nm in diameter and filamentous with a length of 300 nm or more [1, 5] (Figure 3). The 
outer layer of both consist of host- derived membrane into which two types of glycoproteins, trimer-
ic HA and tetrameric NA, and the M2 ion channel are inserted. HA spikes are abundant on the virus 
surface exceeding the number of NA molecules 4 fold, and the number of M2 channels 10-100 fold 
[5, 9]. Below the membrane, the viral matrix enclosing the core is formed by the M1 protein. Influen-
za A core consists of the nuclear export protein NEP (also known as the non-structural protein 2, NS2) 
and the ribonucleoprotein complex (RNP). RNPs contain viral genomic RNA and heterotrimeric RNA-
dependent RNA polymerase. Each polymerase molecule consists of two ‘polymerase basic’ (PB1, PB2) 
and one ‘polymerase acidic’ subunits (PA) [5, 10]. Table 1 briefly summarizes the structural compo-
nents of Influenza A virion indicating their function.  
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Figure 3. Structure of Influenza A virion. Schematic representation of Influenza A with virion components de-
picted (left, adapted from Lars Hangartner). Zernike phase contrast electron micrograph of ice-embedded in-
fluenza A viruses (right, modified from [11]). 
The genome of influenza viruses consists of 8 segments of negative-sense, single-stranded viral 
RNA [1, 5]. Segments 1,3,4,5,6 encode only one protein (PB2, PA, HA, NP, NA respectively). Segment 
2 usually encodes only the PB1 polymerase subunit, however some strains also express the accessory 
protein PB1-F2 from this segment using an alternate reading frame [12]. M1 and M2 proteins are 
both expressed from segment 7 with the latter one arising from alternative splicing [13]. Segment 8 
encodes the interferon antagonist protein NS1 and, by mRNA splicing, also the NEP/NS2 protein. 
Each of the 8 segments ends with noncoding regions and has a helical hairpin made of highly con-
served sequence on one side of the genome [1, 5, 14]. These conserved RNA stretches serve as 
recognition sites for the viral RNA-dependent RNA polymerase. Noncoding vRNA ends contain also 
the mRNA polyadenylation signal and packaging signals necessary for virus assembly. 
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protein function segment encoding 
PB2 polymerase subunit, 
cap recognition 
1 
PB1 polymerase subunit, 
endonuclease activity, 
elongation 
2 
PB1-F2 (optional) pro apoptotic 2 
PA polymerase subunit 3 
HA receptor binding, membrane fusion 4 
NP RNA binding and synthesis 5 
  NA neuraminidase activity, 
virus release 
6 
M1 
 
matrix protein,  
interaction with surface glycoproteins and vRNPs 
7 
M2 acidification of viral lumen, particle disassembly 7 
NS1 IFN antagonist 8 
NEP/NS2 nuclear export of vRNPs 8 
Table 1. Components of Influenza A virion. For each viral protein a short description of its function and the 
number of encoding segment is given. 
3.3 Influenza A ‘life’ cycle 
Attachment to host cell surface 
 Influenza A virus uses its surface glycoprotein HA to bind sialic acid residues on host glyco-
proteins [4](Figure 11 in chapter 3.7). This quite unspecific binding enables infection of many differ-
ent cell types and species, and is contributing to the wide spread of the virus around the globe. He-
magglutinins from different influenza A strains have preferences for the linkage of the sialic acid resi-
dues. Avian strains prefer cells with α2,3 linkage between sialic acid and galactose in the sugar back-
bone [5, 15]. This type of linkage is abundant in avian gut epithelia and therefore Influenza A is an 
enteric virus in birds. Human strains have a preference for α2,6 linkage which is predominant in the 
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upper respiratory tract. However, epithelial cells in the lower respiratory tract also contain the α2,3 
linkage which means that humans can be infected with avian strains [16]. Due to limited accessibility 
of the lower respiratory tract for virus particles (comparing with upper respiratory tract) this type of 
infection is less likely but also more dangerous. Human infections with avian influenza strains are 
usually associated with severe pneumonia and fatality rate over 60% [17]. Details about the molecu-
lar recognition of host cell receptors are provided in chapter 3.5.2.1. 
Virus entry and release into cytoplasm 
 Once the virus particle is attached to cell surface, it gets internalized into endosomes by  en-
docytosis. Following acidification of endosome HA molecules undergo structural rearrangement lead-
ing to fusion of the viral and vesicle membrane[1, 4, 5]. In parallel, the M2 ion channel pumps pro-
tons inside the virion which leads to acidification of the viral lumen, disruption of viral protein- pro-
tein interactions and finally particle disassembly. The virus RNPs are then released into cyto-
plasm[18]. 
Viral RNA synthesis 
RNPs are further transported into cell nucleus through the host’s importin α/β pathway that 
recognizes nuclear localization signals on RNPs [5, 19]. Once arrived in the nucleus, the RNA-
dependent RNA polymerase (RdRp) synthesizes two types of transcripts: mRNA and antigenomic 
RNAs that are complementary, positive-sensed copies of the genomic RNA (cRNA). The mRNA is ex-
ported from the nucleus and translated in the cytoplasm into viral proteins. Synthesis of viral mRNA 
is unique in this term that the polyA tail is transcribed directly from a stretch of uracil residues pre-
sent at the 5’ end of each RNA segment. Furthermore, the mRNA receives its cap structure from host 
mRNA molecules in a process called ‘cap snatching’ [10]. Briefly, the viral RdRp simultaneously binds 
viral and cellular mRNA molecules. Binding to host mRNA is most possibly mediated by the PB2 sub-
unit of RdRp. Once both mRNA molecules are associated with RdRp the PB1 subunit cleaves the 
capped 5’ end of the host mRNA using its endonuclease activity. This capped 10-13nt long RNA is 
then used as a primer for viral mRNA synthesis by PB1 [1, 20]. In contrast the antigenomic RNA 
serves as a template for the production of negative-stranded vRNA progeny [1, 5] . 
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Nuclear export and virus assembly 
Viral mRNA is exported from nucleus into cytoplasm by the same machinery used for host cell 
mRNA [5]. It becomes associated with ribosomes at the ER and viral protein expression begins [21]. 
Following successful translation, properly folded HA, NA and M2 proteins contain apical sorting sig-
nals which direct them through the Golgi to the plasma membrane where they await newly synthe-
tized RNPs. RNPs are formed in the nucleus by associating vRNA with viral proteins. It is believed that 
the lately expressed M1 protein redirects vRNPs used for transcription and replication earlier out of 
the nucleus [22]. M1 mediates the interaction between vRNA and NP as well as with NEP. The latter 
one is the driving force for translocation of RNPs from nucleus into cytoplasm. Once in the cytoplasm 
RNPs are brought in contact with the surface proteins HA, NA and M2- an interaction probably medi-
ated by M1. 
Virus release 
 It is assumed that accumulation of M1 protein on the cytoplasmic side of host membrane ini-
tiates virus budding [1, 5]. vRNPs present at the same site are being incorporated into the budding 
virus. This process seems to be regulated by packaging signals on the vRNA segments that ensure 
formation of complete particles [23]. Following budding, progeny virus particles stay attached to cell 
surface due to interaction of HA with sialylated glycoproteins [4, 5]. This interaction is abolished by 
the enzymatic activity of NA cleaving off sialic acid residues on both host and viral glycoproteins. This 
sialidase activity of NA not only releases virus particles from cell surface but also prevents them from 
aggregation with each other. 
3.4 Epidemiology and economical impact  
Seasonal flu 
Each year Influenza A and B viruses infect hundreds of millions of people worldwide. Even 
though virulence of circulating strains is far lower than for pandemic flu, approximately half a million 
individuals succumb to influenza infections every year [1, 24]. There are currently two subtypes of 
Influenza A viruses circulating in human population: H1N1 and H3N2. The first subtype has most pos-
sibly accidentally been reintroduced into circulation in 1977 whereas the latter emerged during pan-
demic in 1968 (see below) [1]. Both subtypes are subject to antigenic drift, which means that each 
year new variants appear that have evaded the preexisting herd immunity sufficiently to cause a 
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seasonal epidemic. In the northern hemisphere, the flu season usually peaks between January and 
April, whereas in the southern hemisphere, outbreaks occur from May to September [25, 26]. This 
seasonality of Influenza A infections is believed to be associated with the low relative indoor humidi-
ty that may prolong the half-life of virus particles [1]. However this hypothesis is not in agreement 
with some experiments performed under controlled conditions as well with the fact that in tropical 
areas, like Southeast Asia, epidemics strike during rainy season. 
Seasonal influenza mostly affects children age 2 and below, the elderly and people with under-
lying conditions [26]. The incidence of symptomatic influenza infections requiring hospitalization in 
the first 2 groups is around 10 times higher than for people age 1 to 44 (1 in 270 vs 1 in 2900, respec-
tively) [1, 27]. In general, annual flu affects 10 to 20% of population however this number can reach 
50% in case of a pandemic. The most common symptoms of infection include fever, nose discharge, 
fatigue, depression, diarrhea, body aches and sore throat [1, 25]. In severe cases, which are mostly 
caused by H3N2 viruses, pneumonia and secondary bacterial infections may lead to systemic failure 
and death with highest morbidity reported in elderly. 
Influenza pandemics 
As mentioned above, antigenic drift attributes to the emergence of new variants of circulating 
strains each year. However, it is the antigenic shift that is responsible for introduction of completely 
new virus types into the human population to which there is usually no preexisting immunity [1, 25, 
26]. First convincing reports about influenza pandemics reach back to 16th century when in year 
1580 an outbreak started in Russia and spread to Africa and Europe [28]. However, based on histori-
cal data, it is believed that Influenza A was causing local epidemics already in ancient civilizations 
[29]. First reliable epidemiological reports were collected between 1889 and 1892 when H2N2 (or 
H3N8) viruses caused a pandemic [25]. Soon after, the H2N2 (or H3N8) subtype was replaced by 
H3N2. Furthermore, H1N1 subtype was introduced into human population possibly in 1908 and was 
cocirculating with the aforementioned H3N2. The epidemiological situation was steady until 1918 
when the most severe Influenza A outbreak took place. The so called ‘Spanish flu’ killed 20 million 
people worldwide within a year [25, 26]. However, this is believed to be an underestimate and the 
real number may have reached 50 million casualties. The pandemics started most possibly in Fort 
Funston in Kansas with a single soldier falling sick after having contact with pigs [1]. In the first of 3 
phases, H1N1 spread rapidly around the globe. Although highly infectious it was causing mild symp-
toms similar to seasonal flu and affecting mostly young children and elderly. This changed dramati-
cally in August 1918 when a more virulent form emerged that started the second pandemic wave. A 
sudden increase in morbidity and mortality was observed among young people aged 15 to 35, a phe-
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nomenon that is still not completely understood. In general the ‘Spanish flu’ had a very high mortali-
ty rate reaching 2,5% (comparing to 0.1% in seasonal Influenza) with more than 99% of deaths affect-
ing individuals younger than 65 (comparing to 10% for seasonal virus) [1, 25]. During second and 
third wave, patients were showing severe but typical influenza symptoms that in many cases devel-
oped into tracheobronchitis or secondary bacterial pneumonia leading to death. Some individuals 
have been identified post mortem with hemorrhagic lungs further confirming extreme virulence of 
the pandemic strain [25]. This severe virulence have been attributed later to the hemagglutinin pro-
tein and, to a lesser extend, to viral polymerase [30, 31]. Another factor contributing to high morbidi-
ty and mortality was the poor health condition of individuals after World War I. ‘Spanish influenza’ 
outbreak ended in 1919 but drifting variants of the H1N1 virus were circulating for the next 40 years. 
In 1957, viruses of the H2N2 subtype emerged in Southern China causing the ‘Asian influenza’ pan-
demic and completely replacing the H1N1 virus (Figure 4). Within a year the H2N2, a reassortant 
between human and avian viruses, caused 1 million deaths. In 1968, an H3N2 subtype containing 
avian hemagglutinin caused the ‘Hong Kong’ pandemics with an impact comparable to “Asian influ-
enza’. The H3N2 virus spread rapidly around Asia, Australia and USA via military personnel returning 
from Vietnam. Luckily, the severity of this outbreak was modest most possibly due to preexisting 
immunity to N2 protein in human population [1]. From 1977 to present, the H3N2 subtype is co-
circulating together with H1N1-bearing viruses that have probably been accidentally released from 
research facility in Russia or China, and that have caused a mild pandemic that was affecting individ-
uals mostly in USSR and China with morbidity almost entirely limited to people age 25 or less. 
Since the ‘Russian flu’ in 1977 two fatal Influenza A pandemics were feared. In 1997 avian 
H5N1 virus spread in poultry in Hong Kong infecting in parallel individuals working or visiting animal 
markets [32]. Although the infection was rapidly contained and no human-to-human transmission 
occurred, this was the first time an avian virus was reported to cause such lethal infection in humans. 
Since then variants of H5N1 virus circulate in poultry, sporadically infecting people with a mortality 
rate reaching 60% [1]. The second high risk event took place in 2009 when a new H1N1 strain, a mul-
tiple reassortant between human, avian and swine viruses, emerged in Mexico killing approximately 
18 000 people worldwide [33]. Although at that time WHO called this outbreak a pandemic it is be-
lieved that this particular virus was not a serious threat to the human population. 
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Figure 4. Chronological representation of Influenza A pandemics and epidemics. The upper part of the graph 
depicts influenza pandemics highlighted in grey boxes. Each pandemic introduces a new subtype into circula-
tion as shown. Lower part indicates seasonal virus subtypes that were circulating in human population in the 
past. Adapted from Lars Hangartner. 
Influenza in animals 
Influenza A is capable of infecting many species including birds, dogs, cats, swine, horses, 
whales and seals [1]. Of major importance from the economical point of view are outbreaks in poul-
try. One of the most extreme cases was the aforementioned outbreak in 1997 in Hong Kong [34]. The 
highly pathogenic H5N1 strain showed 70-100% mortality rate. In total 1.5 million domestic birds 
have been either killed by the virus or culled. Due to rapid intervention, the spread of the virus was 
temporarily contained until 2001 when H5N1 first reappeared in Hong Kong causing later a severe 
outbreak in 2003 in Vietnam [1, 35, 36]. Up till now 100 million of domestic birds have been killed 
due to this outbreak around the world and the virus continues to cause substantial damage in poultry 
especially in Egypt and Indonesia. H5 and H7 avian subtypes have been reported to cause significant 
loss in poultry since 1950s [1]. The most dramatic outbreaks took place in Pennsylvania (H5N2, 1983, 
17 million birds killed), Pakistan (H7N3, 1995, 3.2 million birds killed) and Netherlands (H7N7, 2003, 
30 million birds killed) [1, 34].  
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Economical impact 
The wide spread of Influenza A virus both in humans and animals has a significant economic 
impact each year. Several studies showed that financial loss due to seasonal flu is counted in billions 
of dollars in the US alone. A recent analysis performed by Molinari and colleagues in 2007 pointed 
out that the annual influenza epidemics (both A and B) account for 3.1 million hospitalized days, 31.4 
million outpatient visits and a medical cost around $10.4 billion [37]. However, it has to be taken into 
account that the cost of medical treatment is only a small percentage of the total bill. The combined 
economic loss (work and school absence, changes in customer consumption patterns, loss related to 
deaths etc) related to seasonal flu was evaluated in this study for $87.1 billion (data for US popula-
tion in 2003). This seems to be in agreement with the recent estimates of US$ 71-167 billion made by 
WHO [38]. 
Although seasonal influenza epidemics seem to be very costly, their economic burden would 
be very minor comparing to a real pandemic. According to the estimates of World Bank from 2008, a 
pandemic with similar death rates as during Spanish influenza would possibly cause a global GDP 
decrease by 4.8% (3 trillion US$) [39, 40]. Even a mild outbreak like the Asian flu is predicted to 
shrink the GDP by 2%. Similar studies have been performed for US only suggesting, that a pandemic 
affecting 15-35% of population would cost between $71.3 billion and $166.5 billion (as for 1999) [41]. 
What has to be kept in mind is the economic burden related to avian influenza outbreaks in 
poultry. H5 and H7 subtypes have been infecting poultry since a long time leading to millions of killed 
or culled birds [1]. A good example is the outbreak of H7N3 subtype from 2004 in British Columbia, 
Canada. Approximately 17 million animals have been killed leading to loss of CAN$ 380 million [42]. 
Noteworthy, this number is only part of a total cost of such outbreak. Even more severe economic 
impact in such cases is related to changes in consumer habits, decreased poultry import and loss of 
trust. 
3.5 Hemagglutinin- the major surface antigen of Influenza A virus 
3.5.1 Structure  
Influenza A hemagglutinin (HA) is a type one membrane protein comprising approximately 550 
amino acids [43]. It contains a transmembrane domain near the C-terminus and short cytoplasmic 
tail. HA consists of 2 subunits, HA1 and HA2, which are generated by proteolitic cleavage of the HA0 
precursor (see below) and which are linked with a disulphide bond. In its mature form, HA is a homo-
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trimer of dimers of 220 kDA and 135 Å in length. The dimer contains two domains: a membrane-
distal globular head and a membrane-proximal elongated stem (Figure 5). The globular head is com-
posed of HA1 residues 52 to 275 (H3 numbering) that mainly form β-sheets. The stem consists of the 
C- and N-terminus of HA1 (residues 11 to 51 and 276 to 329) and HA2. It forms a characteristic triple 
coil-coiled structure of α-helices. Each of the HA dimers has a receptor binding site located in head 
portion and fusion peptide, necessary for virus entry, at the N terminus of HA2 in stem. 
 
 
 
3.5.1.1 HA processing- from HA0 precursor to mature glycoprotein 
HA is encoded by segment 4 of Influenza A genomic RNA [5]. Once the segment is transcribed, 
the mRNA is exported into cytoplasm and associated with ribosomes that drive protein synthesis. HA 
is expressed as HA0- a monomeric precursor protein [1, 43]. Folding of HA0 starts already during 
translation in parallel with the high mannose glycosylation [21]. Sugar residues are recognized by 
calnexin, a chaperon protein which supports further folding steps. Approximately 5 minutes after 
polypeptide chain termination, all intramolecular disulphides are formed and the HA0 monomer be-
comes DTT resistant. At this step the globular head is properly folded whereas stem region is still 
immature. Correctly folded homotrimers are assembled 5-10 minutes later in the ER or the ER-Golgi 
intermediate compartment. HA is then brought to cell membrane and incorporated into virus parti-
cles [5]. 
Figure 5. Structure of Influenza A hemagglutinin. Ribbon 
representation of HA1 (dark yellow) and HA2 (blue) subunits 
of hemagglutinin with protein surface depicted in transparent 
grey (prepared with PyMOL software, DeLano Scientific LLC, 
PDB entry 1MQL). 
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HA proteins require three major modifications to mature and become fully functional [4]. First, 
glycosylation is necessary to acquire a proper fold [21, 44]. It has been shown that complete deglyco-
sylation leads to missfolded HA as the protein can not interact with the folding chaperon calnexin. 
Moreover, glycosylation is essential to overcome immune response [4]. Sugar residues on HA are 
synthesized by cellular machinery, and are therefore recognized as ‘self’. This helps the virus to pre-
vent formation of antiviral antibodies, or impairs binding of pre-existing antibodies. Second modifica-
tion is palmitoylation of the three Cys residues present in the transmembrane region (one Cys) and 
cytoplasmic tail (two Cys) [1]. Mutation of those residues in a H1 virus led to loss of infectivity, 
whereas in case of a H3 virus, the impact on infectivity was moderate [45, 46]. The last modification 
is a proteolitic cleavage of the HA0 precursor into the HA1 and HA2 subunits. Cleavage releases the 
fusion peptide crucial for virus entry into host cell [4, 43]. In some of HA subtypes, the cleavage site 
Q/E-X-R is most likely recognized by tryptase Clara produced by Clara cells in the bronchiolar epithe-
lium. This type of cleavage occurs either on the cell surface or on released virus particles. In case of 
some avian strains from the H5 and H7 subtype, cleavage occurs intracellularly [4, 47]. These strains 
contain a so-called polybasic region with a R-X-R/K-R motif that is recognized and cleaved by subtil-
isin-like enzymes such as furin and PC6. 
3.5.1.2 Antigenic sites 
The antigenic sites on HA have been extensively studied using x-ray crystallography, antibody-
selected mutants and sequence analysis. All sites are located in the globular head and have been 
shown to share two features [1]. First, they mostly have a loop-like structure and are extensively 
glycosylated. Second, they can accept amino acid substitution without affecting HA fold and function. 
There are 5 antigenic sites identified: H3 HAs contain site A made of a loop formed by aa residues 
140-146, site B containing a loop (aa 155-160) and α-helix (aa 188-198), site C formed by antiparallel 
sheet at the base of head portion, site D located close to trimeric interface and site E situated be-
tween C and A on the side of the head. Similar sites have been identified for H1 (Ca1, Ca2, Cb, Sa, Sb), 
and H2. Antigenic sites were shown to accumulate point mutations leading to the emergence of anti-
genic variants. A good example is the human H3 subtype circulating since 1968. Between 1968 and 
2013 residues 142 through 146 and 155 through 160 have all been substituted, some of them multi-
ple times [4].  
3.5.1.3 Hemagglutinin subtypes 
There are currently 17 HA subtypes known. Sixteen of these subtypes are divided into 2 phylo-
genetic groups that contain several clades [48, 49] (Figure 6). New subtypes are described over time, 
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e.g. in 1980 only 12 subtypes have been reported [50]. All subtypes besides H17 are maintained in 
aquatic birds, the primary reservoir for Influenza A viruses. H17 has been discovered in fruit bats in 
2012. Each species has a set of subtypes by which it is preferentially infected. H1, H2 and H3 are 
found in humans, H3 and H7 infect equines and H1, H2, H3, H5 and H9 circulate in swine [1, 25, 26, 
34]. Significant differences in amino acid composition are observed within each subtype and even 
more between each other. For instance, past and present human H3 isolates may differ in up to 20% 
whereas subtypes can only share as little as 30% of aa sequence [1, 4]. Surprisingly, despite this se-
quence variation hemagglutinins maintain proper fold and function. This phenomenon might be at-
tributed to the fact that mutations in HA mostly accumulate in the globular head which seems to be 
tolerant to change. In contrast, the stem portion containing the sophisticated membrane fusion ma-
chinery, is relatively conserved [48, 51]. 
 
 
3.5.2 Function 
3.5.2.1 Receptor binding and specificity 
Hemagglutinin binds sialic acid on host glycoproteins with affinities in low millimolar range [4]. 
Binding is mediated by hydrophobic interactions and hydrogen bonds [47]. Each monomer of Influ-
enza A hemagglutinin has a receptor binding site that contains a set of conserved amino acids (Tyr98, 
Trp153, His183, Tyr195) at its tip, and three conserved structural elements, the 130- and 220-loops 
and the 190-α-helix at the edges [4, 47].  Mutational study showed that residues at positions 98 and 
183 are absolutely essential for receptor recognition, whereas substitution of amino acids at posi-
tions 153 and 195 may only partially inhibit receptor binding. It is believed that due to very low affini-
Figure 6. Phylogeny of Influenza A virus he-
magglutinin. Group 1 (blue) and group 2 (red) 
are shown including clade division and sub-
types (H1 to H17). Figure was prepared based 
on the alignments of 6592 recent HA protein 
sequences from the NIH Flu database. 
Adapted from Lars Hangartner. 
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ty multiple HA molecules have to be involved in interaction with host receptors to allow efficient 
virus attachment to cell surface [47]. 
Although sialic acid is present on various glycoproteins in many species, different HAs show a 
clear receptor binding specificity. Avian and equine viruses bind sialic acid with α2,3-linkage to galac-
tose, human viruses prefer a α2,6-linkage and swine viruses interact with both [1]. Structural studies 
revealed that in case of avian HA the sugar is bound in an extended conformation whereas human 
viruses HAs bind the glycan in a bent conformation [43, 47]. Mutation experiments showed that only 
few residues are responsible for maintaining receptor specificity e.g. amino acid substitutions Q226L 
and G228S change the H5 preference from avian to human type of sialic acid linkage. Recent data 
suggest that similar mutations occurred in case of the Spanish flu H1N1 strain where H1 of avian 
origin was adapted to recognize human receptors and caused a worldwide pandemic [1]. 
3.5.2.2 Membrane fusion and virus entry 
A second important function of HA is mediating the membrane fusion. The main structural el-
ement involved in this process is the fusion peptide, comprising the first 10 N-terminal amino acids of 
HA2 subunit [4]. After proteolitic cleavage of the HA0 precursor the released fusion peptide is hidden 
in a negatively charged cavity in the HA stem. Once the virus particle is internalized into endosome, 
and the pH in endosomal compartment drops below 6 (values between 5 and 6 have been de-
scribed), the HA protein undergoes extensive structural rearrangements [5, 52] (Figure 7). Thereby, 
the globular head is displaced aside, and the flexible loop between A and CD-helix in the coiled-coil 
stem structure acquires an α-helical conformation and pulls the aforementioned A-helix along. The 
fusion peptide leaves the stem's cavity as it is being pulled up by the A-helix. This structural rear-
rangement displaces the fusion peptide by over 100 Å from its initial location, and results in its inser-
tion into the endosomal membrane[1]. In this manner, a bridge between viral and endosomal mem-
brane is established. Parallel insertion of fusion peptides from  several HA molecules finally opens a 
pore in both membranes, and the vRNP particles are released into cytoplasm[5]. Noteworthy, fusion 
can occur at higher pH in case of specific HA mutants. It has been shown that viruses selected in 
presence of amantadine (weak base increasing the endosomal pH) can fuse membranes at neutral 
pH [4, 53]. 
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Figure 7. Structural rearrangement of hemagglutinin at low endosomal pH. Upon acidification of endosomal 
compartment the loop (orange) connecting A (red) and CD (yellow) helix in HA2 subunit adopts a helical con-
formation and pulls up the fusion peptide (purple) towards endosomal membrane. In parallel the HA1 subunit 
is dislocated to enable membrane fusion. Modified from [4] 
3.5.3 Antigenic properties 
3.5.3.1 Nature of antibody response to hemagglutinins 
Antibodies to HA, NA, NP, M1 and M2 proteins can be detected following infection with Influ-
enza A viruses [54]. Among these, the humoral responses to HA and NA have proven to clear the 
virus and to provide protection from re-infection[1]. Multiple studies have shown that the level of 
serum antibodies to HA and NA correlates with restriction of virus replication in the respiratory tract 
[55]. Antibodies to HA neutralize the infectivity of Influenza A by several different mechanisms (see 
chapter 3.6 for details).When passively transferred in mice, they can provide protection even in the 
HA1
HA2
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absence of B or T cells [1, 56]. This observation further stresses the crucial role of humoral immunity 
in clearing Influenza A viruses. During the course of infection, three isotypes of antibodies specific for 
HA are produced: IgA, IgG, IgM. All three classes are present on mucosal surface with the IgA and IgM 
isotypes being the most abundant. Of these, the secreted IgA has been shown to be sufficient to pre-
vent infection and to provide resistance to antigenically similar strains for 3 to 5 months after initial 
infection [57]. 
The antibody response to HA has a limited duration time and usually only protects against 
similar Influenza A strains [1]. Two factors contribute to this. First, the serum IgG and mucosal sur-
face IgA levels significantly decrease during the first year after the initial infection. Second, new in-
fluenza A viruses with redecorated antigenic sites emerge every year or every few years (Figure 8). 
Such viruses are usually not recognized by antibodies elicited by the previous form of the virus [4, 
51]. For a long time it has been believed that the repertoire of serum antibodies to HA is very limited. 
Indeed the vast majority of HA specific antibodies bind to the highly variable globular head, and are 
relatively easily escaped by the virus. Nevertheless, it has recently been shown that following infec-
tion or vaccination, antibodies binding the conserved HA stem are elicited in humans [58-61]. Corti 
and colleagues proved that these stem-reactive mAbs are present at a very low concentration in hu-
man sera of many individuals and that their production is further boosted by vaccination. Although 
these antibodies can neutralize Influenza A, at the concentrations they are present in serum neutrali-
zation of virus is not possible. Moreover, the same sera can neutralize pseudotype viruses (with a 
much lower density of HA distribution on surface) emphasizing difficulties in accessibility of the stem 
epitope on full virus particle. 
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Figure 8. Variability of Influenza A hemagglutinin. Changes in amino acid composition between subtypes (left) 
and within the H1 subtype (right) have been depicted in gradient colors using the Shannon’s entropy algorithm. 
Residues that are not changing or are changing only rarely are shown in grey whereas residues being the sub-
ject of frequent mutations are shown in magenta or green. Figure was prepared based on alignments of 6592 
recent HA protein sequences from the NIH Flu database (left) and based on the alignments of 8219 non-
identical H1 sequences from the NIH Flu database (right) using PyMOL software (DeLano Scientific LLC). 
Adapted from Lars Hangartner. 
3.6 Antibodies binding to Influenza A hemagglutinin 
3.6.1 Subtype specific antibodies  
Following Influenza A infection or vaccination, the majority of produced antibodies is strain 
specific. Some of these antibodies may show cross-reactivity to homosubtypic strains, i.e. belonging 
to the same subtype. The very limited breadth of these antibodies, however, arises from the fact that 
they usually bind to epitopes on the genetically highly variable hemagglutinin head [51]. Strain- and 
subtype-specific mAbs have been widely used in the past to describe the antigenic sites of various 
Influenza A isolates arising from antigenic drift (either natural or selected in vitro). For instance, Ger-
hard and colleagues selected a set of A/Puerto Rico/8/1934 (H1N1) antigenic variants by passaging 
the parental strain in presence of various monoclonal antibodies. They have further analyzed these 
variants by testing their binding to 58 anti-HA mouse mAbs [62]. They have found that viruses clus-
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tered into 4 groups corresponding to 4 distinct antigenic sites on the H1 molecule (see chapter 
3.5.1.2 for details). In 1982 testing several other escape mutants with a set of 32 additional murine 
mAbs has discovered the 5th antigenic site [63]. Similar studies have been performed to describe the 
antigenic properties of H3 hemagglutinin and later also for H2 HA where a 6th unique antigenic site 
has been revealed in the stem region [64-66]. 
Recently a set of human antibodies with broad cross-reactivity within the subtype has been al-
so described. In 2009 Kubota-Koketsu and colleagues reported several mAbs isolated from human 
PBMCs using hybridoma technology [59]. Some of these antibodies, like clones B-1 and D-1, showed 
binding to several antigenically distinct H3N2 viruses. B-1 and D-1 epitopes have been mapped at the 
side of HA globular head- a portion that seems to be conserved to some extend in the H3 subtype. 
Interestingly, although potently neutralizing, those mAbs showed very poor hemagglutination inhibi-
tion (HI) suggesting other mechanisms for virus neutralization rather than blocking the receptor-
binding site. Whittle et al have described another interesting human monoclonal antibody, termed 
CH65, in 2011 [67]. This mAb has been shown to neutralize 30 out of 36 tested H1N1 strains. This 
broad cross-reactivity results from the binding of CH65 to the relatively conserved HA receptor-
binding pocket. The antibody inserts its CDRH3 loop into the pocket mimicking to some extended the 
binding with sialylated receptor. 
3.6.2 Heterosubtypic antibodies 
3.6.2.1 Monoclonal antibodies cross-reactive to HAs from phylogenetic group 1 
Identifying antibodies capable of neutralizing several HA subtypes has long been a goal in the 
field of Influenza A studies. In 1993 the first such heterosubtypic monoclonal antibody C179 has been 
described [68]. It was isolated from mice that have been repetitively immunized with A/Okuda/1957 
(H2N2) virus. C179 showed a broad cross-reactivity, and neutralized viruses from the H1, H2, H5 and 
H9 subtypes [69]. However, little binding without neutralization has been reported for H6 isolates. 
Noteworthy, the antibody did not bind any virus from phylogenetic group 2 HAs. In several animal 
studies, C179 protected to various degree mice that were lethally challenged with H1, H2 and H5 
viruses [70]. Initial epitope mapping using escape variants showed that residues at position 318 in 
HA1 and 52 in HA2 are absolutely crucial for C179 binding, and indicated the existence of a highly 
conserved epitope in the stem of the HA protein. This epitope was distinct from the previously de-
scribed epitopes in the antigenic sites present on the globular head. Recently, the crystal structure of 
C179 in complex with HA from A/Japan/305/1957 (H2N2) has been solved, confirming the interaction 
of the antibody with HA stem [71] (Figure 9). It is now known that C179 utilizes the heavy and light 
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chains to bind residues on both the HA1 and HA2 subunits. In the heavy chain HCDR1 and HCDR3 
loops are involved in the recognition of a hydrophobic groove in proximity of the fusion peptide 
whereas Trp34 in LCDR1 has been shown to interact with Lys38 in HA2. 
 
Figure 9. Epitope recognized by mAb C179. (A) Crystal structure of Jap57/H2-Fab c179 complex. One HA/Fab 
protomer of the trimeric complex is colored with HA1 in green, HA2 in light blue, Fab heavy chain in magenta, 
Fab light chain in orange. N-linked glycans shown as spheres are colored by atom type. The two remaining 
protomers are colored in gray. (B) Residues in HA1 (green) and HA2 (violet) recognized by Fab c179 (modified 
from [71]). 
In 2009, two groups reported almost in parallel the discovery of a new class of broadly cross-
reactive human, monoclonal antibodies recognizing the HA stem [48, 51]. mAbs CR6261 and F10 
were selected independently from human phage display libraries. CR6261 and F10 were able to neu-
tralize majority of viruses from phylogenetic group 1, and protected mice from lethal challenge with 
H1 (CR6261, F10) and H5 (CR6261). However, no interaction with group 2 HAs has been detected. 
Like C179, neither of these mAbs did inhibit hemagglutination but rather neutralized the virus by 
preventing the structural rearrangement of HA at low pH. However, both of the newly discovered 
antibodies used exclusively their heavy chains to contact HA which is different from C179. The in-
volvement of a single chain in epitope recognition is quite common for clones selected from phage 
display libraries and is believed to be an artifact of the selection process. The crystal structures of 
CR6261 in complex with H1 or H5 HA revealed that this antibody uses mainly HCDR1 and HCDR2 
loops to bind the antigen while the involvement of HCDR3 is limited. This feature is pretty uncom-
mon as in majority of antibodies crystallized to date a long HCDR3 contributes most to the binding. 
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Also, the structure of F10 in complex with H5 showed an involvement of all 3 HCDRs. Moreover, be-
sides interacting with HA stem residues, HCDR3 also stabilized the conformation of HCDR2. Further-
more FR3 of F10 has been found to support the binding of HCDR1 and HCDR2. In case of both mAbs 
the recognized epitope contains stem-associated HA1 residues and elements of HA2 (fusion peptide, 
A-helix). Interestingly, the heavy chain of CR6261 and F10 evolved from the same VH 1-69 germline 
family. A characteristic feature of VH 1-69 is the presence of Met/Iso/Leu/Val at position 54 and Phe 
residue at position 55 [72]. These hydrophobic residues at the tip of HCDR2 are crucial for recogni-
tion of hydrophobic patches on HA stem. Similar interaction involving VH 1-69 HCDR2 has been previ-
ously reported for broadly cross-reactive mAbs binding other proteins (e.g. HIV gp120) [73, 74].  
There are 2 subtle structural differences in the CR6261 and F10 epitope between group 1 and 
2 HAs [48, 51, 75] (Figure 10). These differences are believed to cause the lack of binding of these 2 
mAbs to group 2 viruses. First, position 381 (subscript 1 denotes HA1 and 2 denotes HA2 subunits) in 
four out of 6 members of group 2 HAs is occupied by Asn (His in group 1) and glycosylated. The pres-
ence of this sugar was predicted to decrease the binding of CR6261 and F10. Indeed, CR6261 binding 
to H5 mutant glycosylated at position 381 was significantly reduced. Second, the Trp212 residue is 
differently oriented in group 1 and 2. As this residue is recognized by Phe at the tip of HCDR2 in both 
CR6261 and F10 and significantly contributes to binding, the different orientation is believed to com-
pletely abolish the interaction of these 2 mAbs with group 2 viruses.  
   
In 2010 another group 1 cross-reactive antibody was discovered. mAb PN-SIA49 has been ini-
tially described as neutralizing multiple H1N1 isolates [76]. Later, the same antibody has been proven 
to neutralize all group 1 subtypes besides H9 and to provide protection from lethal challenge with 
H1N1 and H5N1 viruses [77]. Interestingly, the heavy chain of PN-SIA49 belongs to germline family VH 
3-23 suggesting a different binding mode compared to CR6261 and F10. Competition for HA binding 
Figure 10. Structural differences between group 1 and group 
2 hemagglutinins in the epitope recognized by mAb F10. An 
overlay of H1, H5 and H9 (group 1, shaded red and yellow, 
PDB 1RU7, 2IBX and 1JSD) and H3 and H7 (group 2, shaded in 
blue, PDB 1MQL and 1TI8). Residues interacting with mAb 
F10 were depicted including the two crucial positions 381 and 
212 (subscripts 1 and 2 denote residues in HA1 and HA2 sub-
unit, respectively). Modified from [48]. 
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with C179 and alanine scanning studies mapped the PN-SIA49 epitope in HA stem, further supporting 
the notion that this part of hemagglutinin bears highly conserved structures. 
3.6.2.2 Group 2 cross-reactive monoclonal antibodies 
One antibody with cross-reactivity limited to hemagglutinins from phylogenetic group 2 has 
been reported to date [78]. mAb CR8020 was isolated from a human donor using hybridoma tech-
nology. This antibody binds to most group 2 HAs (H3, H7, H10, H15) with affinities ranging from ~1 to 
35 nM with the exception of H4 and H14 subtypes that were bound with KD ~500 and ~1000 nM, 
respectively. Similarly, CR8020 was found to neutralize various H3, H7 and H10 isolates with IC50 val-
ues ranging from 1.7 to 13.1 µg/ml. However, it failed to neutralize H4-subtyped virus. Furthermore, 
CR8020 protected mice from A/Hong Kong/1/1968 (H3N2) or A/Chicken/Netherlands/621557/2003 
(H7N7) infection in both prophylactic and therapeutic setups. Crystal structure of CR8020 in complex 
with H3 revealed that the mAb uses its both chains to bind a stem epitope in a close proximity to the 
viral membrane, and thus much more membrane proximally than the epitopes described for CR6261 
and F10. The binding area was almost entirely composed of residues of the HA2 subunit residues 
with the exception of residue 325 in HA1. As expected, CR8020 neutralized virus particles by prevent-
ing the structural rearrangement of HA at the pH of membrane fusion- a mechanism previously de-
scribed for other HA stem reactive antibodies [48, 51, 75, 79]. A detailed comparison showed that 
the epitopes of CR8020 and CR6261 are distinct with only 2 residues (Asp192 and Leu382) shared 
between them.  
Although the CR8020 epitope is relatively conserved in group 1 HAs, no binding to group 1 he-
magglutinins have been observed. Two structural differences may account for this observation [78]. 
First, Gln or Thr residues are present in group 2 at the HA2 position 34 which is occupied by bulkier 
Tyr in group 1. Structural simulations showed that such Tyr would possibly cause steric hindrance 
with HCDR3. Indeed, binding to an H3 Gln34Arg mutant was reduced over 100 fold, indicating the 
importance of position 34 in CR8020 epitope recognition. Second, a conserved carbohydrate is pre-
sent at Asn211 in group 1. This sugar is believed to clash with HCDR1. 
3.6.2.3 Pan Influenza antibodies 
Selection of neutralizing antibodies recognizing subtypes from both HA groups has been a chal-
lenging goal for many years. The discovery of such a broadly cross-reactive mAb and the highly con-
served HA epitope recognized by it was long considered necessary for the design of a universal Influ-
enza A vaccine. In 2011 Corti and colleagues described the first human monoclonal antibody FI6 that 
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was able to neutralize members of both phylogenetic groups [75]. FI6 showed cross-reactivity to H1-
H10 and H13 HAs in ELISA and neutralized multiple pseudotyped virus strains from sybtypes H1, H5 
and H7 as well as various H1N1 and H3N2 Influenza A isolates. Furthermore, the antibody provided 
protection to mice infected with a lethal dose of A/Puerto Rico/8/1934 (H1N1) or HK-x31 (H3N2) 
viruses. Interestingly, based on study with FI6 mutants deficient in complement or FcR binding, the in 
vivo activity of the antibody has been identified as largely dependent on its effector functions. This 
explained why FI6, moderately potent in in vitro neutralizing assays, showed high efficacy in animal 
protection experiments. 
Structural studies revealed that FI6v3 (an optimized FI6 variant) binds to the HA stem using 
both heavy and light chain. FI6 recognizes residues in the fusion peptide and the A-helix, similarly to 
the CR6261 and F10 antibodies. One striking difference between these antibodies is that in case of 
FI6 most of the binding is mediated by HCDR3. The long and flexible HCDR3 in FI6 is inserted into a 
hydrophobic pocket in the F subdomain of HA stem where it binds Trp212 using Phe residue. The 
flexibility of FI6 HCDR3 is believed to enable the binding of this Trp residue in both HA groups. In 
contrast, the previously described group 1 cross-reactive mAbs CR6261 and F10 use a Phe residue at 
the tip of their short HCDR2 loops [48, 51]. The limited flexibility of these loops most possibly does 
not allow the binding of Trp212 in group 2 HAs. Other differences between these mAbs involve the 
interaction of HCDR2 in FI6 with the carbohydrate connected with Asn381 and the contact made by 
LCDR1 with fusion peptide. Interestingly, the aforementioned carbohydrate, believed to decrease the 
binding of CR6261 and F10 to some group2 HAs, is being displaced by FI6 upon binding. 
Dreyfus and colleagues have recently reported another group-1 and 2 neutralizing monoclonal 
antibody referred to as mAb CR9114 [79]. It has been selected from phage libraries based on human 
B cell genetic material. Remarkably, CR9114 showed binding to HAs belonging to group 1 and 2 of 
Influenza A as well as to hemagglutinins derived from both lineages of Influenza B (the Victoria and 
Yamagata lineage). In general CR9114 bound all tested HAs with KD values in the low nanomolar 
range. Furthermore, the mAb neutralized A/New Caledonia/20/1999 (H1N1) and 
A/Wisconsin/67/2005 (H3N2) isolates whereas no neutralization of Influenza B viruses was shown. 
Surprisingly, even though not neutralizing Influenza B in vitro, CR9114 completely protected mice 
from lethal challenge with B/Florida/4/2006 and B/Malaysia/2506/2004 at concentrations 5 and 15 
mg/kg. This suggests that the in vivo potency of this mAb is mainly dependent on its effector func-
tions as was previously described for the other group 1 and 2 cross-reactive mAb FI6. Furthermore, 
CR9114 protected mice from lethal infection with A/Puerto Rico/8/1934 (H1N1) and A/Hong 
Kong/1/1968 (H3N2) at similar doses as reported for Influenza B experiments. 
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Data from crystal structure of CR9114 in complex with several Influenza A HAs shed some light 
on the remarkable cross-reactivity of this antibody. As expected, CR9114 interacts with HA stem. 
Surprisingly, the epitope is almost the same as for the group 1 cross-reactive mAb CR6261. Both an-
tibodies use their VH 1-69 encoded heavy chains and FR3 region to recognize a hydrophobic patch on 
HA stem without any binding coming from the light chain. The reason for a broader CR9114 cross-
reactivity comparing with CR6261 arises from several subtle differences in the mode of epitope 
recognition. First, both antibodies bind the Trp212 residue using a Phe on the tip of HCDR2 but in 
case of CR9114 a higher plasticity of this loop enables it to interact also with the Trp212 of group 2 
and Influenza B HAs. Further, binding of CR9114 displaces the carbohydrate at position 381 in some 
of the group 2 hemagglutinins as well as the glycan at position 3321 of Influenza B HA. Last, CR9114 is 
capable of adopting the larger Asn residue at position 49 in HA2 of group 2 viruses. This residue is 
occupied by Thr in group 1 HAs. 
Although the epitopes of CR9114 and FI6 almost completely overlap, mAb FI6 is approaching 
the binding site at a different angle which probably restricts its breadth to Influenza A viruses [75]. 
Therefore, CR9114 is the first reported pan Influenza A and B antibody. The structural data collected 
in the CR9114 study are currently being applied to the design of a universal influenza vaccine. 
In 2012, a study by Hu et al. reported several different group 1 and 2 cross-reactive mAbs [58]. 
They were isolated from human B cells and are believed to have been induced by vaccination with 
the 2009 pandemic H1N1 vaccine. Selected mAbs showed neutralizing activity of variable potency, 
depending on the tested subtype. Most of these antibodies contain VH 1-69 derived heavy chains 
and all of them bind the HA stem. mAbs 1F2, 1F4 and 1E1 have been further shown to recognize a 
linear epitope corresponding to the fusion peptide. 
3.6.2.4 Molecular evolution- from germline antibodies to pan-flu monoclonals 
The isolation of broadly cross-reactive, neutralizing, HA-binding antibodies has been a mile-
stone in the field of influenza research. However, one important question remained: ‘How such anti-
bodies are generated?’ The study by Lingwood and colleagues answered this question in detail. The 
molecular evolution of the VH 1-69 based, group 1 cross-reactive mAb CR6261 was investigated, 
starting with the germline ancestor of CR6261 (CR6261-GL) [72]. The CR6261-GL IgG molecule was 
not capable to bind HA. However, once expressed as surface IgM, the resulting B cell receptor was 
shown to be engaged by binding of HA, and tyrosin kinase signalling necessary for antibody matura-
tion was triggered. Mutational study revealed that binding of germline VH 1-69 as an IgM molecule is 
dependent on the interaction of HA with Ile53 and Phe54, thus the two germ-line encoded hydro-
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phobic residues at the tip of HCDR2. Furthermore, and as expected, only somatic mutations in the 
heavy chain were necessary to restore full activity of CR6261, confirming the lack of HA binding by 
the light chain. A low number of somatic mutations in the heavy chain is a characteristic feature of 
VH 1-69-encoded HA-specific antibodies. On average only 14 amino acids substitutions have been 
reported for these mAbs. The study further confirmed that only 7 of these mutations are necessary 
to restore full binding and neutralizing activity of CR6261. These somatic mutations are located in 
HCDR1 and FR3 region. The HCDR1 mutations Thr28Pro and Ser30Arg have been shown to expose 
the Phe29 that is buried in the structure of germline antibody. In the FR3, a Phe is introduced at posi-
tion 74, and together with Phe29, it makes essential contacts with a hydrophobic patch on HA stem. 
A similar evolutionary study has been conducted for the group 1 and 2 cross-reactive FI6 anti-
body that is encoded by VH 3-30 and VL 4-1 germline genes [75]. FI6 was compared with its germline-
reverted ancestor FI6-GL, closely related but only group 1-specific FI370, and FI6/370-BP, a hybrid 
antibody that contains all the somatic mutations shared between FI6 and FI370. FI6, FI370, FI6/370-
BP and FI6-GL bound HA from group 1 whereas only FI6 could strongly bind a hemagglutinin from 
phylogenetic group 2. 
Based on these data it can be speculated that the VH 1-69 and the combination of VH 3-30 and 
VL4-1 germline genes evolved as universal pattern recognition molecules binding to conserved 
epitopes on influenza hemagglutinin [72, 75]. It seems that the evolution of 2 of such germlines was 
necessary as some individuals contain a homozygous mutation Phe54Leu abolishing the binding of 
VH 1-69 to HA. 
3.6.2.5 Heterosubtypic antibodies recognizing epitopes outside HA stalk 
At least one broadly cross-reactive, neutralizing antibody binding an epitope outside HA stem 
has been reported to date. mAb S139/1 was shown to react with H1, H2, H3, H5, H9 and H13 sub-
typed viruses whereas neutralization could be demonstrated for H1, H2, H3 and H13-expressing vi-
ruses [80]. No neutralization was found for H5, H9 and Influenza B isolates. S139/1 prevented he-
magglutination of erythrocytes suggesting that the antibody neutralizes the virus by blocking HA 
receptor-binding site. Escape variants generated by extensive passaging of H1N1, H2N2 and H3N2 
viruses in the presence of S139/1 indeed had mutations at positions 156, 158 and 193 (H3 number-
ing). This maps the recognized epitope at the tip of globular head region in close proximity of recep-
tor binding site. Thus, the S139/1 epitope resembles more a unique, conserved antigenic site. Indeed 
a partial overlap between the site bound by S139/1 and antigenic site Sb (H1) or B (H3) has been 
reported. 
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3.7 Influenza A treatment and prevention- past, present and future  
Each stage of the Influenza A virus ‘life’ cycle has been studied in terms of inhibition of viral 
replication using various compounds (Figure 11). In this chapter a brief overview of the currently 
marketed and experimental influenza drugs is given. Further, currently available vaccines used for 
influenza prevention and recent advances in this field are reported. 
 
Figure 11. Inhibition of Influenza A virus at different stages of its ‘life’ cycle. The interaction of Influenza A 
virus with host cell receptors is mediated by hemagglutinin. Once bound the virus is internalized into endo-
some. The low pH of endosome triggers the membrane fusion process and virus disassembly. vRNPs are further 
transported to the nucleus where the viral replication and mRNA synthesis occurs. The mRNA is next utilized to 
express viral proteins that interact with each other and vRNPs to form new virions. Each step of the infection 
and replication cycle can be targeted by drugs. Examples of such drugs are depicted in grey boxes. From [81]. 
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3.7.1 Small molecule inhibitors 
3.7.1.1 Neuraminidase inhibitors  
Oseltamivir and zanamivir, two neuraminidase inhibitors, are the only marketed influenza 
drugs besides the M2 inhibitors. Oseltamivir and zanamivir have been developed based on the struc-
ture of 2-deoxy-2,3-dihydro-N-acetylneuraminic acid- the prototype NA inhibitor that was lacking in 
vivo activity [1, 82]. Both drugs interact with the NA receptor binding pocket by structurally mimick-
ing sialic acid and show activity against Influenza A and B viruses. The effectiveness of these drugs 
largely depends on the time of administration. Studies showed that the treatment has to start within 
48 hours from the onset of symptoms in order to benefit from the therapy [83]. Oseltamivir is orally 
administered whereas zanamivir is inhaled. Since both drugs are interacting with Glu276 in NA, mu-
tations in close proximity to this residue confer resistance. Several different resistant variants have 
been reported to date. The H274Y and R292K mutants are insensitive to oseltamivir with the latter 
one moderately affecting the binding to Zanamivir [84]. Residues H274 and R292 interact with the 
aforementioned Glu 276 enabling its rotation necessary to accommodate the large hydrophobic side 
chain in oseltamivir [83]. The occurrence of oseltamivir-insensitive virus variants changes during each 
season, and is variable among different subtypes [47]. In 2008-2009, almost 100% of seasonal H1N1 
isolates were resistant whereas the H3N2 and Influenza B viruses remained sensitive [85]. In contrast 
since 2010 the oseltamivir resistance in all circulating human viruses has been low (including H1N1 
isolates). Resistance to zanamivir has been marginal till now and oseltamivir-resistant isolates have 
been sensitive to zanamivir. 
Recently two other neuraminidase inhibitors have been approved for use in humans in treat-
ment and prevention of Influenza A and B infections [86]. Peramivir and laninamivir are modified 
versions of oseltamivir and zanamivir [83]. Peramivir binds NA in a similar way to oseltamivir and 
therefore H274Y-bearing virus mutants are also resistant to peramivir. However, the resistance to 
peramivir is less pronounced than to oseltamivir.  For laninamivir, no naturally occurring resistant 
variants have been reported so far. Nevertheless, it is believed that this compound, structurally simi-
lar to zanamivir, will not be active against zanamivir resistant viruses.  
3.7.1.2 M2 inhibitors 
M2 protein consists of 4 transmembrane helical regions and a C-terminal cytoplasmic helix 
[84]. The transmembrane helices form a pore that transfers protons inside the virus particle at low 
endosomal pH. This acidification of the virus lumen leads to virus uncoating and RNP release. Proton 
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transfer is mediated in a pH-dependent, coordinated action of His37 and Trp41 residues. Amantadine 
and rimantadine (adamantine derivatives), two M2 ion channel inhibitors, have been approved for 
treating humans and are in use since many years. X-ray structure and NMR studies showed a differ-
ent mode of action for these compounds. Amantadine binds inside the proton channel, close to 
Ser31 residue, physically blocking the pore. Rimantadine interacts with outer surface of the M2 heli-
ces, in the close proximity of Trp 41. It is believed to lock M2 in the ‘closed’, inactive conformation.  
Several different mutations in M2 (L26F, V27A, A30T, and S31N) are responsible for viral re-
sistance to amantadine and rimantadine [87]. These mutations have propagated in circulating Influ-
enza A viruses during last 2 decades. As a result, 100% of human isolates tested in 2009 showed re-
sistance to both drugs. Emerging resistance and CNS side effects related to use of these drugs ren-
dered amantadine and rimantadine inadequate for treatment of Influenza A infections in humans. 
However, several new adamantine derivatives and non-related compounds blocking the action of M2 
have been identified in recent years. Among the adamantine derivatives, one of the most potent is 
Spiro[piperidine-2,2′-adamantane]. This compound and its modifications have been shown to block 
the M2 in a similar manner as amantadine, and were also active against some amantadine resistant 
mutants. In the group of non-adamantine compounds the 2-[3-azaspiro(5,5)undecanol]-2-imidazoline 
(BL-1743) and its derivatives showed significantly higher potency than amantadine but were not able 
to neutralize adamantine resistant variants. Nevertheless, BL-1743 is being used now as starting 
point in the design of drugs that can overcome reported M2 resistance, especially to the predomi-
nant S31N mutation. 
3.7.1.3 Hemagglutinin inhibitors 
Tert-butylhydroquinone (TBHQ), is a small aromatic compound that is effective in neutralizing 
Influenza A viruses [88]. However, action of TBHQ is limited to group 2 viruses. TBHQ interacts with 
hemagglutinin and blocks the structural rearrangement of the molecule that is necessary for mem-
brane fusion. X-ray crystallography revealed that TBHQ binds to the HA stem between CD-helices of 
two neighboring HA monomers, and slightly above epitopes recognized by CR6261, F10, FI6 and 
CR9114 antibodies. Detailed analysis of TBHQ epitope showed structural differences at this site be-
tween group 1 and 2 HAs. The lack of binding to group 1 viruses was attributed to an extra turn made 
by A-helix in close proximity to TBHQ binding site. Such turn is only present in group 1 HAs, explain-
ing the limited cross-reactivity of this compound. 
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3.7.2 Monoclonal antibodies 
A considerable number of broadly cross-reactive antibodies binding influenza hemagglutinin 
has been isolated during the recent years [89]. The aforementioned mAbs CR6261, F10, FI6, CR8020, 
CR9114 etc. proved to be effective in protecting animals lethally infected with corresponding viruses. 
This has raised the hope of using such antibodies in a therapeutic or preventive setup in humans, too 
[90]. As more and more Influenza A isolates display resistance to currently marketed small-molecule 
inhibitors, these antibodies may be the only alternative in treatment of influenza infections. Moreo-
ver, such monoclonal antibodies have several advantages over chemical compounds used as drugs at 
the moment. First, they target highly conserved epitopes. For some of these mAbs, generation of 
escape mutants was not possible whereas for others it required extensive passaging of virus in pres-
ence of limiting dilution of given antibody [48, 51, 75, 79]. It is conceivable that using a cocktail of 
multiple mAbs, e.g CR9114 with FI6, would be effective against any emerging virus and no mutations 
could confer resistance to such treatment. Second, the bioavailabilty, pharmacokinetics and side 
effects for these biologicals may be improved compared to oseltamivir or zanamivir. Since these an-
tibodies were isolated from human combinatorial antibody libraries or human B cells, they should be 
well tolerated. Last, the number of HA cross-reactive mAbs reported to date already vastly exceeds 
the number of currently available drugs giving the possibility to adjust the treatment to patient’s 
needs. On the other hand the manufacturing process of monoclonal antibodies is more tedious and 
expensive compared to that of small molecules. However, it has to be noted that recent advance-
ments in mAb production (improved expression yields, decreased cost) provide hope for introducing 
such antibodies on the market. 
3.7.3 Computationally designed proteins 
In 2011, Fleishman and colleagues described a completely new approach for generating pro-
teins binding to the conserved epitopes on influenza A HA [91]. The group used computational design 
to identify residues and scaffolds complementary to chosen HA epitope. The new binding proteins 
have been constructed in a two-stage process. First, a set of disembodied amino acids have been 
docked into the epitope in energetically favorable configurations. These amino acids have been cho-
sen to provide interactions common in protein-protein complexes. Second, sets of selected disem-
bodied amino acids have been applied to complementary scaffolds. In total 88 different designs have 
been tested resulting in 2 HA binding proteins, HB36 and HB80. Both proteins have then been sub-
jected to affinity maturation that increased their KD values to the low nanomolar range. Crystal struc-
ture showed that HB36.3 (a matured variant of HB36) interacts with the HA stem and the recognized 
epitope closely resembles the computationally designed one. Further, this epitope is overlapping the 
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one recognized by CR6261. In a follow up study from 2012, both proteins have been further im-
proved in terms of affinity and cross-reactivity however no interaction with group 2 HAs was report-
ed [92]. Noteworthy, the F-HB80.4 variant neutralized virus particles of recent H1N1 subtypes. These 
data bring hope into fast development of proteins with desired properties. Such proteins, inexpen-
sive in production, could be potentially used to treat broad spectrum of Influenza A infections. 
3.7.4 Influenza A vaccines 
3.7.4.1 Seasonal Influenza vaccines 
First prototypes of seasonal influenza vaccines have already been described in 1930s [1]. At 
this time, culturing of Influenza A strains in embryonated hen eggs has been established, and provid-
ed large quantities of viral material necessary for vaccination. During World War II, first experimental 
inactivated vaccines have been administered to US military personnel starting the era of widespread 
vaccination against flu.  
Nowadays, inactivated seasonal vaccines are based on 3 types of viruses: an H1N1, an H3N2, 
and a B virus. Influenza strains used in these trivalent vaccine are annually selected, based on the 
analysis of circulating viruses and a prediction of the viruses to be predominantly circulating in the 
next influenza season [93]. It is crucial to properly match the virus as this type of vaccines only pro-
vide protection against the inoculated or very closely related strains.  
For the production, selected viruses are grown in embryonated hen eggs. The allantoic fluid 
containing virus particles is then harvested, and particles are purified using either centrifugation or 
column chromatography [94]. The virus is next inactivated with formalin or beta-propiolactone and 
treated with detergent to solubilize the membrane. Such trivalent inactivated or split vaccine (TIV or 
SV) is currently used as standard for vaccination against seasonal influenza. 
Recent advances in the production of inactivated vaccines 
There have been several improvements in the process of vaccine production over the years. 
First, production yields have been increased by growing reassortant viruses containing the HA and 
NA antigens from selected seasonal isolate in the genetic background of the robust H1N1 A/Puerto 
Rico/8/1934 strain [1, 94, 95]. Second, the introduction of additional virus purification techniques 
during the manufacturing process has provided vaccines that contain less by-products and thus have 
a lower incidence and severity of side effects. Third, new production techniques such as removing 
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the polybasic region enabled to amplify strains that normally would be lethal to chicken embryos [1]. 
These techniques make vaccine production, e.g. against highly pathogenic, potentially pandemic 
H5N1 viruses possible. Alternatively, amplification of highly pathogenic viruses can now be per-
formed in cell culture. In 2012 FDA approved the use of Flucelvax, the first influenza vaccine pre-
pared by growing viruses in cell culture [96]. This approach has several advantages over the egg-
based manufacturing process: it is faster, it yields viruses that do not drift genetically from the paren-
tal strain used as inoculum and it is not dependent on seasonal availability of eggs and SPF flocks that 
lay these eggs. One of the last improvements in the current process of seasonal vaccine preparation 
has been made in the field of split vaccines. In 2013 FDA approved Flublok, the first vaccine com-
posed of recombinantly expressed hemagglutinins from each H1N1, H3N2 and B strains [97]. Inter-
estingly, the vaccine is effective against all tested, circulating human isolates and not only the vaccine 
strains. 
Efficacy of inactivated vaccines 
Efficacy of seasonal, inactivated vaccines ranges from 45 to 85% [1, 97, 98]. This value depends 
on the type of vaccine and several other factors, for instance the degree of the immunological match 
between the vaccine strain and the circulating viruses. Further, better immune responses are ob-
served when the vaccinated individual has previously been infected with a virus of the same subtype. 
In case of the introduction of a new subtype into the human host, vaccination against this subtype 
has to be performed at a higher dose [99]. In general, protection from virus challenge has been cor-
related with antibody titers to HA. Although responses to NA and activation of CTLs can also be de-
tected, these two factors contribute much less to protection [1]. Furthermore, the breadth of HA-
specific antibodies induced by vaccination is influenced by the disease history. If the individual is 
seronegative, the induced HA antibodies are mostly strain-specific. In contrast, vaccination of sub-
jects that have previously experienced multiple influenza infections is more likely to elicit broadly 
cross-reactive sera. Moreover, antibody breadth may depend on the vaccine formulation as it was 
mentioned above for Flublok. HA antibody titers decrease significantly within the first year after vac-
cination. This observation, combined with the limited protection provided against antigenically drift-
ed seasonal strains, requires that vaccination should be performed annually. 
Live attenuated vaccines 
Live attenuated vaccine (LAV) has been first introduced into US market in 2003 under the 
brand name 'Flumist' [100]. In 2011, FluMist was also approved in the European Union under the 
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market name 'Fluenz' [101]. These vaccines have been developed to overcome some of the limita-
tions of inactivated vaccines. One major drawback of inactivated vaccines is that they have a lower 
efficacy in those groups that are at high risk of influenza infection (e.g. the elderly)[1]. Another disad-
vantage is that inactivated vaccines induce a very limited antibody repertoire, providing protection 
only to the vaccine or closely related strains. Live attenuated vaccines have been shown to overcome 
some of those problems. This property can be partially attributed to the fact that live vaccines, be-
sides stimulating antibody response, also induce T cells [102]. Furthermore, the intra nasal applica-
tion of LAV potently stimulates the immune response at the primary site of virus entry and replica-
tion [103]. This seems to provide a better protection than the systemic immune response induced by 
inactivated vaccines. 
LAV consists of viruses whose growth has been attenuated by multiple passages at a lower 
temperature (25⁰C). An example of such virus is A/Ann Arbor/60/60 (H2N2) strain [1]. This virus can 
not efficiently replicate at the usual body temperature of 37-38 ⁰C that is normally permissive for 
wild type viruses. To facilitate the production of the vaccine, a universal manufacturing system based 
on A/Ann Arbor/60/60 (H2N2) has been designed. In this system, the aforementioned H2N2 virus is 
reassorted with selected seasonal strains. The resulting vaccine strain contains the genetic back-
ground of A/Ann Arbor/60/60 with NA and HA genes from the circulating strain. 
Multiple clinical studies proved the superior performance of LAV over inactivated vaccines es-
pecially in children. The work by Belshe and colleagues showed a high efficacy (93%) of LAV in sero-
negative children 15 to 71 months of age [104]. This knowledge has further been extended in a clini-
cal study from 2008. Here a comparison with inactivated vaccine showed that LAV vaccinated pa-
tients aged 2-5 years had 52.5% and 54.4% less cases of influenza illness following infection with a 
matched or mismatched virus, respectively [105]. Moreover, a study from 2010 proved that the vac-
cine provides a certain level of cross-protection against drifted and mismatched Influenza B strains in 
children 6 months to 6 years [106]. Currently, several other live attenuated vaccines against influenza 
are being developed with an H5N1 vaccine being of major interest [107, 108]. 
3.7.4.2 Experimental vaccines 
Although widely used since decades, and substantially improved in recent years, traditional 
seasonal influenza vaccines are inefficient. Their major limitation is that they do not provide hetero-
typic protection. This implies that they have to be formulated annually based on predictions of the 
upcoming seasonal strains [93, 94]. As a result, vaccine delivery is significantly delayed and the vac-
cine itself may not be effective if the vaccine strain is a poor match with the actually circulating 
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strain. Many studies have been performed to address this issue and to produce a universal flu vac-
cine. Induction of antibodies as well as T-cell response has been tested [109]. Furthermore, various 
influenza proteins have been included in experimental formulations. A brief overview of these is pro-
vided below. 
3.7.4.2.1 M2e vaccines 
M2e, the external domain of M2 protein, has long been considered as a candidate for the de-
velopment of a universal Influenza A vaccine. This short stretch of 18-24 amino acids is present on 
virus surface and is highly conserved amongst all Influenza A viruses [110, 111]. Thus, inducing a ro-
bust immune response to it could possibly provide a heterosubtypic protection. Although there are 
some differences in amino acid composition between the human and avian-type of M2e, it has been 
shown that serum specific for the first type of M2e is also cross-reactive to the second type. 
Even though theoretically promising, M2e used as an antigen has one major limitation: the lack 
of immunogenicity [110]. This issue has been successfully addressed by incorporating multiple M2e 
molecules into virus-like particles (VLPs) in connection with highly immunogenic proteins. A good 
example here is the fusion of M2e with Hepatitis B core (HBc) protein [112]. VLPs based on this con-
struct contain approximately 240 HBr-M2e fusion proteins organized in 120 dimeric spikes. Such VLPs 
proved to induce a strong immune response in mice as evaluated based on high serum M2e-specific 
antibody titers. Moreover, mice vaccinated with such immunogen were protected against virus chal-
lenge even after intranasal (i.n.) vaccine administration. The mechanism of M2e-based protection 
has long been unclear. It was known that antibodies induced against M2e are not neutralizing. M2 
protein containing M2e is incorporated into cell membrane during virus replication cycle. Due to high 
density of surrounding glycoproteins, surface exposed M2e is possibly not accessible to B and T-cells. 
However, it has been proven in several studies that surface exposed M2e is bound by immunogen-
induced antibodies [110]. These antibodies activate antibody-dependent cell cytotoxicity (ADCC) 
leading to the elimination of infected cells and thus virus clearance. Phase I clinical trial performed by 
Acambis Inc (currently Sanofi Pasteur) using HBr-M2e VLPs (ACAM-FLU-A vaccine) showed that high 
titers of M2e antibodies are induced after 2 immunizations in almost all subjects. Potency of this and 
other M2e based vaccines in humans is currently studied. 
Several different approaches to M2e-based vaccines have been employed. In the study by 
Price et al. entire M2 and NP genes have been incorporated into an adenoviral vector [113]. These 
recombinant adenoviruses have been used as i.n. vaccine in mice and provided protection against 
viruses of the H1N1, H3N2 and H5N1 subtypes. Detailed analysis showed induction of high antibody 
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titers and specific T-cells as possible reasons for the reported clearance of Influenza A infections. In 
another investigation, Powell and colleagues used nanoparticles that mimic natural pathogens and 
induce potent immune response in absence of adjuvants [114]. These nanoparticles were coated 
with several different layers of oppositely charged polypeptides with M2e peptide included in the 
external layer. Mice immunization with M2e nanoparticles elicited high titers of M2e specific anti-
bodies. Furthermore, the same study using several different nanoparticle constructs with various 
immunogens showed that there is no antibody response to the particles themselves. This is a signifi-
cant advantage comparing to other delivery vectors like the aforementioned adenoviruses, as it ena-
bles multiple vaccinations without antibody-related clearance of the vector [115, 116]. Furthermore, 
nanoparticles were shown to be internalized by dendritic cells (DC) and to potently induce CD4 and 
CD8 T-cells specific to the delivered antigen [114]. Thus, this nanoparticle-based approach seems to 
be very promising in designing a universal Influenza A vaccine but requires further investigation.  
3.7.4.2.2 Vaccines based on pseudoparticles 
Another approach to the design of a universal Influenza A vaccine has been reported by Powell 
and colleagues in 2012 [102]. They used pseudotyped virus based on the H1N1 A/Puerto Rico/8/1934 
strain as immunogen. These pseudoparticles (termed S-FLU) contained the complete genome of the 
virus but were not capable to undergo a complete replication cycle. Attenuation of infectivity was 
achieved by introduction of multiple mutations into the HA gene that rendered it dysfunctional. 
Therefore, pseudoparticles were amplified in 293T cells transfected in parallel with a plasmid con-
taining an intact HA sequence to complement in trans and to enable budding of infective virus. Alt-
hough expressed in cytoplasm, the defective HA was rapidly degraded and available for surface dis-
play to T cells. Mice vaccinated twice with S-FLU were completely protected from challenge with 
H1N1 and H3N2 viruses. The protection was later attributed to activation of antigen-specific T cells. 
Furthermore, no significant antibody response to HA was detected unless large doses of S-FLU were 
used. It has also been proven that the mutated HA gene is not crucial for eliciting protective immune 
response. The modified version of S-FLU, containing eGFP instead of mutated HA gene, performed 
comparably well to the HA construct. 
The S-FLU presents multiple advantages over other vaccine designs. First, it elicits heterosub-
typic protection. Second, S-FLU does not present the risk of providing a novel HA gene that could be 
reassorted with circulating seasonal strains. This has been a particular concern in case of life attenu-
ated vaccines. Third, even though S-FLU is using a similar approach as adenovirus-based gene deliv-
ery, much lower doses of S-FLU pseudoparticles are necessary for immunization. In the study, doses 
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4 orders of magnitute lower than for similar adenovirus therapies have been sufficient to elicit strong 
immune response. This further emphasizes the potency of such immunogen. 
3.7.4.2.3 Vaccines based on recombinant hemagglutinin  
The discovery of broadly cross-reactive antibodies binding conserved epitopes in HA stem has 
become a foundation for the design of a universal influenza vaccine. In recent years several different 
approaches to this subject have been reported [93, 117]. One common feature for all of them is that 
they focus on exposing the previously mapped conserved stem epitopes. Isagawa’s and Palese’s 
groups, have extensively studied multiple HA based constructs in terms of eliciting heterotypic im-
mune response [117-121]. In a study from 2010, Palese’s group reported vaccination with a set of 
‘headless’ hemagglutinins that have been constructed by removing the HA1 portion present between 
Cys 52 and 277 residues [117]. These construct contained the stem related HA1 and all HA2 amino 
acids connected with various linkers. The fold of these proteins has been confirmed using stem-
reactive antibodies and the most promising candidates have been used for mice immunization. The 
vaccination schedule consisted of intra muscle electroporation of plasmid DNA containing sequence 
of a particular construct followed by injection of VLP containing the related protein. H1-based head-
less HA vaccine induced antibodies cross-reactive to H1, H2 and H5 whereas H3-based headless HA 
elicited sera only reactive to the vaccine strain. Although induced sera had limited cross-reactivity 
and did not neutralize the virus in vitro, protection of mice challenged with H1N1 (A/Puerto Ri-
co/8/1934) has been reported for the H1 construct. These data suggested that this type of design is 
insufficient. Therefore a new approach has been tested. In a study from 2013 several constructs, all 
containing the same stalk (from H1 PR8) but different heads (H9, H6, H5), were tested (chimeras 
cH9/1, cH6/1, cH5/1) [119]. The idea behind this setup is to avoid inducing antibodies towards the 
head portion that changes at each vaccination and focus the antibody response on stalk that stays 
invariant at each step. First, mice were electroporated with DNA containing the cH9/1 chimera. Later, 
animals were boosted with subsequent injections of cH6/1 and cH5/1 as soluble proteins. The vac-
cinated mice were fully protected against challenge with H1N1, H5N1 and H6N1 but no protection 
was reported for H3N2. Furthermore, binding to H2 HA and neutralization of H2N2 virus with IgG 
from vaccinated mice was shown. As H2 subtype was not used in vaccination it was speculated that 
the elicited antibodies recognize the conserved HA stem. 
This and several other studies have shown that using only the stem of HA as an immunogen 
might be not sufficient to elicit cross-reactive sera and to provide a broad protection against viral 
challenge. This might be related to some subtle structural changes that may occur in stem once it is 
expressed without the head. These changes, although not detectable in antibody-based assays, may 
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somehow decrease the breadth of vaccine elicited sera. Therefore other modifications of the system 
have been applied. In the study by Wang and colleagues only a short stem-derived peptide has been 
used as immunogen [120]. This peptide consisting of HA2 amino acids 76-130 (termed LAH for the 
presence of long α-helix) of H3 has previously been described to be recognized by cross-reactive mAb 
12D1. To enhance the antigenicity and extend serum half-life of the peptide, LAH was conjugated to 
keyhole limpet hemocyanin (KLH) and acetylated. Mice vaccinated with LAH-KLH construct had sera 
cross-reactive to H1, H2, H3, H5 and H7 subtypes in ELISA. Further, they were completely protected 
against H3 and partially protected against H5 challenge. Although no protection was seen against H1 
virus the disease was delayed in the vaccinated group. 
3.8 Phage display- a tool to select antibodies with desired properties 
Phage display was first described by Smith et al. in 1985, and is a widely used and powerful 
technology to select high affinity molecules with desired properties from large repertoires [122]. 
Initially only small polypeptides could be displayed on the surface of filamentous phage particles 
[123]. This changed during the last two decades. Many new, optimized scaffolds of displayed proteins 
were designed that enabled recognition and binding of almost every target antigen (e.g. proteins, 
nucleic acids) [124-126]. For phage display, a filamentous phage (e.g. M13) is modified to display a 
binding molecule (e.g. Fab antibody fragments, polypeptides) on its surface for which it also carries 
the genetic information [127]. Such molecule is fused to one of the phage coat proteins in a way that 
it can make interactions with the target of interest. During selection process, phage clones present-
ing binding moiety for the desired target molecule are enriched. The sheer size of phage display li-
braries enables screening of up to 1010 different variants of binding molecules in few relatively simple 
steps. Up till now phage display has been successfully applied in many fields, e.g. selection of high 
affinity synthetic antibodies, selection of molecules with improved stability and folding, selection for 
enzymatic activity.  
During the phage display selection process, the target molecule is usually immobilized on solid 
surface like magnetic beads or plates, and incubated with a phage library that displays a large variety 
of potentially binding molecules [122]. Due to the design of a phage vector only one binding specifici-
ty is displayed per phage particle. After incubation phages that do not bind the antigen are washed 
away. The remaining bound phages are then eluted, amplified in E. coli and used for the next selec-
tion round. Usually 3 rounds of selection are sufficient to obtain clones binding tightly to target mol-
ecule. Each round may differ in the target molecule concentration, time of incubation or wash strin-
gency. By controlling these parameters antibodies with desired properties can be obtained. The se-
lection results in a set of phage clones that are reamplified separately in bacterial host and further 
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tested for binding to the relevant antigen e.g. in ELISA. Due to the fact that each phage clone carries 
the genetic information encoding the displayed e.g. Fab fragment positive clones can be further used 
to amplify the sequence of binding molecule, clone it to another vector and express as soluble pro-
tein/peptide. These can be later evaluated in various experiments like neutralization assays. If the 
obtained molecule only weakly binds the relevant target further affinity maturation using different 
techniques (e.g. error prone PCR, site directed mutagenesis) can be applied. Moreover, molecules 
interacting with an exact area on the antigen may be obtained by introducing appropriate antigen 
design (e.g. sterically blocking access to irrelevant surface) [128]. 
  
Figure 12. Example of phage display selection process. In the phage selection a library of phages displaying 
binding molecules (e.g. Fabs) is combined with the antigen of interest immobilized on solid surface. Phages in 
the library display molecules with different binding specificities (e.g. various CDR composition in Fab frag-
ments). Phage clones that interact with the immobilized target via the Fab fragment are captured, eluted, 
reamplified in bacterial host and used in the following selection round. The resulting clones can be further 
evaluated for their binding properties (as phage particle or as purified Fab) using different assays (e.g. ELISA, 
SPR, microarray). Modified from [127]. 
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4. Results 
4.1 Alternative recognition of the conserved stem-epitope of influen-
za A hemagglutinin by a VH3-30-encoded heterosubtypic antibody 
This is a manuscript in preparation. I contributed in the following way: I prepared the phage 
display library by cloning the genetic material from isolated B cells; mutated, cloned, expressed, puri-
fied and biotinylated the H2 hemagglutinin used for panning; performed selection; expressed and 
purified some of the hemagglutinins used in subsequent assays; validated mAb 3.1 in binding and 
neutralization assays; expressed mAb 3.1 for crystallography study; performed in vivo protection 
assays. I also participated in figure preparation. 
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Alternative recognition of the conserved stem-epitope of influ-
enza A hemagglutinin by a VH3-30-encoded heterosubtypic an-
tibody 
 
Wyrzucki A1, Dreyfus C2, Kohler I1, Steck M1, Wilson IA2, Hangartner L1 
1Institute of Medical Virology, University of Zurich, Switzerland; 2The Scripps Research Institute, La Jolla, USA 
Summary 
Using immobilized hemagglutinin from A/Japan/305/1957(H2N2) in phage display, VH3-30-
encoded human monoclonal heterosubtypic antibody mAb3.1 was isolated. It was found to neutral-
ize influenza viruses from the H1a clade but had no activity against viruses of the H1b clade or of 
phylogenetic group 2. The crystal structure of mAb 3.1 revealed that it contacts the same hydropho-
bic groove in the stem of the HA protein as most other heterosubtypic antibodies, and that primarily 
engages residues of its heavy chain for binding. However, in contrast to the closely related mAb FI6 
that almost exclusively relied on residues of CDRH3 for binding, mAb 3.1 was found to involve resi-
dues from CDRH1, CDRH3 and FR3. Thereby, CDRH1 of mAb 3.1 adopts an α-helical structure con-
formation and engages in very similar hydrophobic interactions with HA as the de novo in silicio de-
signed and affinity matured artificial protein HB36.3. 
Introduction  
Hemagglutinin (HA), the surface protein responsible for receptor attachment and entry of in-
fluenza A viruses, exists in 17 distinct subtypes [1] that can be divided into two separate phylogenetic 
groups. HA assembles as a trimer and is initially synthesized as an inactive form (HA0) that is pro-
cessed to its active form by cleavage into covalently linked HA1 and HA2 subunits. In the viral spike, 
the apical globular head that contains the receptor-binding site is made of the HA1 subunits while 
the stalk region containing the fusion machinery is built by HA2 subunits combined with the N and C-
terminal ends of HA1. Antibodies elicited during infection and immunization bind to highly antigenic 
domains surrounding the apical receptor binding site on HA1, and typically interfere with receptor 
binding [2-5]. As these antigenic sites are also subject to the highest antigenic variation, most anti-
bodies recognizing influenza HA are highly strain-specific, and only recognize the eliciting or closely 
related virus strains. 
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Currently, only influenza viruses of the H1 and H3 subtypes circulate in the human population. 
Yet, cases of zoonotic infections with avian or swine viruses are reported on a regular basis, indicat-
ing that, to some degree, the species barrier is permeable for influenza viruses [6-9]. Although most 
of these infections are relatively benign, zoonotic infections with highly pathogenic avian influenza A 
viruses (HPAI) of the H5N1 subtype are considered to end lethal for more than 60% of all infected 
individuals. Although this number is likely to be an overestimate due to non-reporting of sub-clinical 
and mild cases, it nonetheless underlines the urgent necessity to be prepared for potentially lethal 
zoonotic infections. Moreover, as zoonotic infections are the origin of novel pandemic strains, 
prophylactic or post-exposure treatment of potentially exposed individuals could prove helpful in 
restricting the early spread of emerging viruses. Recent emergences of zoonotic H7N9-bearing virus-
es that are probably capable of human-to-human transmission [10] further stress the need for such 
first line defense treatments. As the usefulness of the currently available drugs is rapidly decreasing, 
alternative treatments e.g. with passively transferred heterosubtypic antibodies, i.e. antibodies that 
neutralize more than one subtype (or even genus) of influenza, could offer an efficient alternative to 
small molecule inhibitors. Moreover, the ability to induce heterosubtypic antibodies by immunization 
would allow for the development of a pan-flu vaccine and would make the annual reformulation and 
application of the seasonal vaccine obsolete.  
The first heterosubtypic monoclonal antibody (hmAb) isolated, C179, was generated in mice 
that were hyperimmunized with an H2N2-expressing human virus around 20 years ago [11, 12]. 
Meanwhile, several human heterosubtypic antibodies have been isolated and their epitopes charac-
terized [13-20]. With the exception of the exclusively group 2-specific heterosubtypic antibody 
CR8020 that binds to a more membrane proximal epitope, all other heterosubtypic antibodies recog-
nize approximately the same epitope on the stem of influenza A hemagglutinin (HA). This epitope, a 
hydrophobic groove that is framed by residues 18-52 and 290-330 of HA1 in combination with 1-21 
and 38-60 of HA2 is very conserved amongst all subtypes of influenza A, and, to some degree, also 
shared with viruses of the B genus [19].  
Quite interestingly, several antibodies binding to this epitope are encoded by the VH1-69 (F10, 
CR6261, CR9114, 3C4) or the VH3-30 (FI6, 1C4) germline genes, and mostly only bind to HA subtypes 
of phylogenetic group 1 (H1, H2, H6, H8, H9, H11, H12, H13, H16). Only recently, monoclonal het-
erosubtypic antibodies capable of neutralizing viruses from both phylogenetic groups have been de-
scribed [16, 19, 20]. To date, six human heterosubtypic antibodies that are not encoded by the VH1-
69 or VH3-30 germline genes have been published (PN-SIA49, 1E1, 1F2, 1F4, 1G1, 3E1)[17, 20]. Five of 
these antibodies use the VH3-23, one the VH4-4 heavy chain germline gene [17, 20]. Also these anti-
bodies are either specific for phylogenetic group 1 [17], or can neutralize viruses from both phyloge-
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netic groups [20]. So far only one antibody that exclusively recognizes HA subtypes from phylogenet-
ic group 2 has been described [15]. 
VH1-69-encoded heterosubtypic antibodies are frequently isolated, and primarily use their 
heavy chain to contact the HA protein. Although germline encoded VH1-69 antibodies devoid of so-
matic hypermutation do not recognize soluble HA, they can trigger B cell receptor signaling when 
engaged by HA as IgM molecule on the surface of B cells [21]. From the available crystal structures, it 
can be deduced that positions 49, 111 and 21 in HA2, as well as position 18 and the presence or ab-
sence of a glycan at position 38 of HA1 account responsible for the main differences between the 
two phylogenetic subgroups [13, 14, 16, 19]. Latter has been shown to be flexible enough to accom-
modate binding of an antibody in its proximity [16, 19]. Antibodies capable of overcoming these dif-
ferences have been demonstrated to achieve this by the flexibility of their complementarity-
determining region (CDR)[16, 19]. VH3-30-encoded FI6, for instance, is characterized by a particularly 
long HCDR3 loop (22 aa) that provides the hydrophobic residues required for the crucial contacts 
with the hydrophobic groove in the stem of HA (i.e. Leu100A, Tyr100C, Phe100D Trp100F). In con-
trast, murine mAb C179 and all VH1-69-encoded antibodies, including CR9114, contact this groove 
with hydrophobic residues from all HCDRs of their heavy chain [14, 19]. Additional contacts can assist 
the interaction of the heavy chain with the hydrophobic groove, and can either include 3 residues of 
LCDR1 (Phe27D, Asn28, Tyr29; FI6), or from FR3 (D72, I or D73, F74; CR6261 and CR9114). 
Results 
Isolation and characterization of monoclonal antibody 3.1 
Using RNA isolated from mature B cells of a healthy donor, a Fab phage display library was 
prepared and used for panning against trimeric baculovirus-expressed HA from 
A/Japan/305/1957(H2N2) [3] that was reversibly immobilized on magnetic beads. The H2 subtype 
was chosen for two reasons: First, antibody mapping suggested that there is an antigenic site in the 
stem of this subtype protein that is not present in other human HA subtypes [2, 3]. Second, the do-
nor of the B cells used for the preparation of the phage library was born in 1976, and should there-
fore be immunologically naïve to the H2 subtype that ceased circulating in humans in 1967. Conse-
quently, antibodies isolated from this donor that are capable of binding H2 are bona fide heterosub-
typic antibodies.  
After four rounds of panning, 13 clones were selected for further characterization. All clones 
possessed virtually the same heavy chain paired to different light chains. The HCDR3 amino acid (aa) 
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sequences (N-CARDLGGYFIRGIMDVW-C) found in all heavy chains suggests a common ancestor aris-
ing from a single IGHV3-30*04, IGHD3-9*01 to IGHJ4*01 recombination event. This notion is further 
supported by the observation that 9 out of 13 heavy chain sequences are completely identical, with 
the remaining clones only displaying a maximum of four nucleotides differing from the consensus 
sequence. The light chain repertoire was more diverse and included 7 distinct kappa and 3 distinct 
lambda light chains (Suppl. Table 1). While the common heavy chain of all clones shared the very 
same VDJ-gene segment usage as mAb FI6 [IGHV3-30, IGHD3-9, IGHJ4*01• 16], none of the light 
chains isolated in this experiment displayed the same IGKV4-1xIGKJ1 genotype of the FI6 light chain 
(Suppl. Table 1). 
Since at that time, data on affinity maturation of FI6 was not yet available, we randomly se-
lected a representative clone based on phage-ELISA data using H2 as coating antigen. This clone, 
referred to as mAb 3.1, expressed the common heavy chain paired to an IGKV1-12 x IGKJ4*01 light 
chain. Interestingly, sequencing revealed that the light chain present in mAb 3.1 hardly displayed any 
somatic hypermutation, and only displayed nucleotide replacements in FR1 causing aa 1 and 2 to 
differ from the reference alleles deposited at IMGT. However, these mutations are most likely an 
artifact arising from serial PCR amplification required for the preparation of a phage display library.  
Specificity of mAb 3.1 
In enzyme-linked immunosorbent assays (ELISA), mAb 3.1 was found to bind to recombinant 
HA proteins from A/Puerto Rico/8/1934(H1N1), and A/Japan/305/1957(H2N2), but failed to bind to 
A/Moscow/10/1999 (H3N2) and A/Fowl plague/Bratislava/1979(H7N7). The EC50 values were calcu-
lated to be 3x10-8 for H1, and 1.8x10-8 g/l for the H2, respectively (data not shown). Using Bio-layer 
interferometry (BLI), Fab fragments of mAb3.1 were also found to bind to biotinylated HA from 
A/duck/Alberta/345/1976(H1N1), A/USSR/90/1977(H1N1), A/Beijing/262/1995(H1N1), A/Solomon 
Islands/3/2006(H1N1), A/Japan/305/1957(H2N2), A/Adachi/2/1957(H2N2), A/Vietnam/1203/2004 
(H5N1), A/turkey/Massachusetts/3740/1965(H6N2). No binding was neither found by ELISA nor BLI 
to A/duck/Alberta/60/1976(H12N5), A/gull/Maryland/704/1977(H13N6), A/black-headed gull/ Swe-
den/4/99 (H16N3), A/duck/Ukraine/1/1963 (H3N8), A/Hong Kong/1/1968 (H3N2), 
A/duck/Czechoslovakia/1956 (H4N6), A/Netherlands/219/2003 (H7N7), A/Fowl 
plague/Bratislava/1979 (H7N7), A/chicken/Germany/N/1949 (H10N7), 
A/mallard/Astrakhan/263/1982 (H14N5), A/shearwater/ W. Australia/2576/79 (H15N9) (Supplemen-
tary Table 2). These data show that mAb 3.1 bound HA proteins from phylogenetic group 1 but failed 
to bind HA proteins belonging to phylogenetic group 2. 
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The antiviral activity of mAb3.1 against at least one representative isolate from subtypes H1 
through H15 was tested. Since pseudo-typed influenza viruses were described to be more easily neu-
tralized than live virus [13], all of our neutralization assays were performed with viable influenza 
viruses. To this end, we established a robust fluorescence-based neutralization assay that employed 
105 infectious units per well, corresponding to a multiplicity of infection of 2 to 3. Using this assay, it 
was found that mAb 3.1 neutralized viruses of the H1, H2, H5, H6 subtypes at half maximal inhibitory 
concentrations in the µg/ml range (Figure 1). Thus, like most VH1-69-encoded and the germline-
reverted variants of FI6, mAb 3.1 was only able to neutralize isolates from phylogenetic group 1. 
However, mAb 3.1 failed to neutralize isolates from the H1b clade that includes the H11, H13, and 
H16 subtypes, and it hardly neutralized isolates from the H9 clade (i.e. H8, H9, H12). The main differ-
ences in the stem epitope between the H1b and the remaining clades are a glycosylation site at posi-
tion 291 of HA1, and the lack of a proline at position 293. As a consequence, interaction of HA1 with 
FR3 residues of mAb 3.1 may be disturbed. However, since the only exception with this respect, H6, 
is well recognized by mAb 3.1, these differences alone are unlikely to be the sole reason for the dif-
ferent recognition by mAb3.1. Indeed, removal of the glycosylation site at position 291 in the he-
magglutinin of A/duck/Memphis/546/1974(H11N9) and reassortment into A/Puerto Ri-
co/8/1934(H1N1) did not improve 3.1-mediatied neutralization sensitivity of the resulting reassort-
ant virus (Figure 2). However, if the removal of the glycosylation site at position 291 was accompa-
nied by the introduction of a Pro at position 293, the resulting virus became partially sensitive to 
neutralization by mAb3.1. In contrast, neither the introduction of a glycosylation site at position 291 
or removal of the proline at position 293 of the hemagglutinin from A/Puerto Rico/8/1934(H1N1) 
altered its neutralization sensitivity. Thus, depending on the structural context, these two residues 
may have a great impact on the neutralization sensitivity to antibodies binding to this epitope. 
In vivo protection 
Encouraged by the neutralization data, we assessed whether passively transferred mAb 3.1 
was able to protect mice from a lethal challenge with A/Puerto Rico/8/34(H1N1). As depicted in Fig-
ure 3, all mice were protected against a lethal challenge with 2 LD50 of A/Puerto Rico/8/34(H1N1) 
when 10mg/kg mAb3.1 were transfused 24h before infection. Also at 3mg/kg, 8 out of 10 mice were 
protected against the same dose of virus in two independent experiments (Figure 3). Weight loss in 
infected animals was considerably attenuated at 10mg/kg with 9 out 10 animals losing less than 15% 
of their initial body weight. Also at 3mg/kg, 7 out the 8 surviving mice lost less than 15% of the initial 
body weight during the course of the infection. In contrast, the weight of all control animals dropped 
below 15% already at day 4. Thus, the in vivo protective capacity of mAb3.1 was comparable to FI6, 
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another VH3-30 encoded monoclonal antibody and in the same range as all other heterosubtypic 
antibodies described. In accordance to 3R recommendations of the Swiss animal welfare authorities, 
we therefore did not perform any further in vivo experiments with other strains, as we did not expect 
any new insights (or surprises) from a replication of these experiments. 
Crystal structure of mAb 3.1 
In order to analyze the molecular interaction with HA, we solved the crystal structure of the 
Fab fragment of mAb3.1 in complex with soluble HA from a pandemic H1N1 influenza virus A/South 
Carolina/1/18(H1N1) at 2.9 Å resolution (Figure 4). Not surprisingly, mAb31 recognizes the same 
hydrophobic groove in the stem as other VH3-30 or VH1-69-encoded antibodies. The epitope consists 
of residues from the N- and C-terminal regions of HA1 (38, 40-42, 289-293, 318), and the N-terminal 
portion of HA2 (18-21, 38, 41, 42, 45, 49, 52, 53, 56), including helix A. mAb3.1 buries a total of ~1333 
Å2  at the interface with HA (686 Å2 for HA and 647 for Fab) and almost exclusively uses residues of 
the heavy chain (Fab3.1 heavy chain contributes 96% of the Fab buried surface area) for these inter-
actions (Figure 4A, Supplementary Table 3). The angle of approach of Fab 3.1 is similar to murine 
antibody C179 and FI6, despite different binding interaction [12, 16]. The VH domain binds using a 
combination of 3 loops, including HCDRs 1 and 3, and the tip of FR3 (Figure 4B). HCDR1 and HCDR3 
account for 85% of van der Waals contacts between Fab and HA, where Phe27 (HCDR1), Tyr99 and 
Phe100 (HCDR3) make many of the key hydrophobic interactions (~50% of van der Waals). Corre-
sponding HCDR3 interactions were observed in the FI6 and C179-HA complexes, where both insert 
two aromatic side chains from their HCDR3 (Tyr99mAb3.1, Tyr98C179 and Tyr100CFI6; and Phe100mAb3.1, 
Phe99C179 and Phe100DFI6) into the hydrophobic groove (Figure 4B). As previously described antibod-
ies (CR6261, F10, C179) or protein designed (HB36 and F-HB80.4) specific to group1 influenza A vi-
ruses, mAb3.1 make a similar interaction with Trp21 placing Phe100 at the tip of HCDR3 at a remark-
ably similar position and orientation (Figure 4A) [12-14, 16, 22, 23]. 
In addition to the HCDR-mediated interactions, residues 74 through 76 of framework region 3 
contact Asn289 and Ser291 of HA1. Like FI6, mAb 3.1 also employs LCDR1 to contact HA2. However, 
in case of mAb3.1, these contacts do not involve the fusion peptide but are formed by van-der-Waals 
interactions of Gln38 located at the N-terminal end of the A helix with Trp 32 of the light chain. In 
contrast to FI6, where a long HCDR3 solely mediates contacts with the hydrophobic grove, mAb31 
employs a combination of HCDR1 and H3 to contact HA protein (Figure 4B). Thereby the membrane 
proximal contacts are made by HCDR3, while the residues of HCDR1 provide the apical interactions. 
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Of note, it was found that the de novo in silicio designed and affinity matured artificial protein 
HB36.3 closely mimicked some of the interactions with mAb3.1. In particular, the α-helical structure 
of HCDR1 is reminiscent of HB36.3’s recognition helix with very similar hydrophobic interactions me-
diated by Phe side chains at position 27 and 100 of mAb3.1 and position 49 and 61 of HB36.3 (Figure 
4B). Comparison with the crystal structure of unbound mAb 3.1 revealed that twisting of HCDR1 
Phe27 in the bound configuration is most likely to trigger this α-helix formation (Figure 4C). Struc-
tural homology search revealed that other VH3-30-encoded monoclonal antibodies, such as 8F9 rec-
ognizing the neutralizing AD-2S1 epitope of the human cytomegalovirus glycoprotein B (gB)[24], B7-
12A2 specific for tetanus toxoid [25], or APU2.16 recognizing polyubiquitin in a linkage-specific man-
ner [26] also display α-helical HCDR1 structures, that can also be found amongst the canonical IgG 
structures [27]. Yet, the striking similarities with HB36.3 demonstrate nicely that in silicio designed 
and in vitro maturated artificial proteins can simulate naturally selected antibody binding pretty well.  
In contrast to most other heterosubtypic antibodies where the light chain was described not to 
be essential for binding, FI6 was found to possess two residues (F27 and R93) in its light chain whose 
reversion to germline-encoded serine drastically reduced the ability to bind to HA proteins of phylo-
genetic group 2 HA, even when introduced individually [16]. However, when the FI6 light chain was 
paired with the heavy chain of 3.1, the hybrid antibody displayed the binding and neutralization pro-
file of mAb3.1, as tested by binding to H1, H3, H7, H12 and neutralization of H3, H4, H7, H10, H12, or 
H15 isolates (data not shown). This indicates that the beneficial impact of these FI6 light chain re-
sides is specific to FI6. 
Discussion 
We have isolated a VH3-30 encoded heterosubtypic monoclonal antibody that neutralizes vi-
ruses from the H1a clade very well and displays low neutralizing activity against the H9 clade. mAb3.1 
contacts a similar epitope in the stem of the HA as all other VH3-30 and VH1-69 encoded antibodies 
and primarily involves residues of the heavy chain, which bind to the hydrophobic groove in this 
epitope. Our finding, together with recently published heterosubtypic antibodies from an H1N1pdm-
vaccinated donor [20], fortifies the predominance of VH1-69 and VH3-30-encoded antibodies in the 
human repertoire of heterosubtypic antibodies. In case of mAb3.1, only 4 out of 10 somatically hy-
permutated residues of the VH gene are actually involved in the binding of the HA protein, suggesting 
that the majority of the binding residues are already satisfactorily encoded in the VH3-30 germline 
gene. However, in contrast to FI6 that predominantly employs residues of HCDR3, mAb3.1 uses a 
combination of both HCDR1 and HCDR3 to contact residues of the hydrophobic groove. Thus, in both 
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VH3-30 encoded heterosubtypic antibodies, diversity generated by recombination in the HCDR3 ap-
pears to be of great importance since in FI6 residues contacting the conserved epitope almost exclu-
sively arise from the antibody gene rearrangement. But also in case of mAb3.1, a good proportion of 
the binding energy originates from hydrogen bonds or hydrophobic interactions of the residues of 
HCDR3. Quite interestingly, both VH3-30-endcoded heterosubtypic antibodies required extensive 
addition of non-templated N-nucleotides. In case of mAb3.1, there is no addition of N1 nucleotides 
but the N2 region contains 17 nucleotides (5'-tcataaggggcattatg-3') encoding for 7 aa (N-FIRIGIM-C), 
two of which (F100, R100B) contribute to binding. In case of FI6, the N-nucleotide additions are even 
more extensive as there are a total of 32 non-templated nucleotides added, 22 nt of which as N1 (5’-
c tcc caa ctg cga tca ctc ctc-3’) and 10 as N2 (5’-cc cag gga tat-3’) nucleotides that also contain key 
residues for heterosubtypic binding (L98, R99). Both antibodies use the D3-9*01 segment that pro-
vides these antibodies with two essential hydrophobic residues that are inserted into the groove. 
Thus, the VH3-30 germline gene appears to provide good framework for heterosubtypic antibodies as 
it provides a HCDR1 that can (or cannot) be used to contact the apical region of the conserved stem 
epitope. However, this framework needs to be combined with D3-9, or another D region capable of 
providing hydrophobic residues, and these need to be sufficiently separated from the germline 
framework by the addition of N nucleotides to be inserted deep into the conserved hydrophobic 
grove in the stem of the HA protein. In contrast to VH1-69 encoded antibodies, the light chain can 
play a supportive role and provide additional free energy for binding of HA. With regard to the con-
tribution of the complementarity determining regions to the overall binding, HCDR1 and 3 using mAb 
3.1 appears to be in between FI6 that primarily uses HCDR3 and VH1-69 encoded antibodies that 
employ all three HCDRs for binding [13, 14, 19].  
Of note, literature search revealed that the VH3-30 and VH3-11 germline genes are suspected 
to be evolutionary selected to encode for CMV-neutralizing antibodies, as most key residues required 
for binding of the linear neutralizing epitope AD-2S1 were already found in these germline genes [24, 
28]. Indeed, structural homology searches using PDBe or DALI search engines identified cytomegalo-
virus neutralizing antibody 8F9 [28] (MJ5; PDB 3EYG), as the structurally most closely related anti-
body. However, a functional relationship would appear highly unlikely. Indeed, neither mAb3.1 nor 
FI6 displayed detectable binding to CMV glycoprotein B in ELISA, excluding a functional overlap be-
tween VH3-30-encoded influenza and CMV-neutralizing antibodies.  
It has been described that germline-reverted CMV-neutralizing antibodies are highly poly- and 
potentially autoreactive [29]. Similar findings have been made for an IGHV3-33-encoded HIV-
neutralizing antibody [30]. It has been speculated that due to the potential autoreactivity of their 
germline antibodies, generation of certain antibody specificities would be more difficult. Accordingly, 
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the VH3-30 germline gene would represent a weak spot in the antibody repertoire that is actively 
exploited by variable viruses. A recent germline-usage evaluation, however, demonstrated that VH3-
30-encoded antibodies are the fourth most frequently entered antibody sequences into the IMGT 
database (as of July 5, 2013). We therefore find it unlikely that a potential auto-reactivity of the 
germline-encoded antibodies can provide a satisfactory explanation for the rare occurrence of het-
erosubtypic antibodies. 
So far, the antigenic particularity of the H1b clade has been underappreciated. As depicted in 
Figure 2, the C-terminal region of HA1 displays considerable differences in the H11, H13 and H16 
subtypes compared to other members of phylogenetic group 1 (except H6). In particular, there is a 
potential N-linked glycosylation site at position 291 and no proline at position 293 in this clade. These 
differences in the proximity of the contacting FR3-residues may perturb binding of heterosubtypic 
antibodies. Indeed, even the broadest antibody described so far, CR9114 appears to be struggling 
with this clade as it failed to neutralize an H11 isolate despite binding decently to recombinant H13 
and H16 HA protein in ELISA [19]. We could show that the removal of the glycosylation site by the 
introduction of a proline at position 293 made H11 more susceptible to neutralization by mAb 3.1. 
However, when the reciprocal mutations were introduced into H1, no effect was seen. No influence 
on the neutralizing activity of FI6 was observed either. Thus, although there is no universal im-
portance of this region on binding of the heterosubtypic antibodies, its composition can have sub-
stantial impact on neutralization by certain antibodies. 
Thus, isolation and characterization of mAb3.1 helped to gain a better insight into the molecu-
lar requirements for binding to the conserved epitope in the stem of the HA protein. Moreover, it 
provided evidence that binding of in silicio and in vitro selected artificial antibodies closely resembles 
that of naturally occurring antibodies. This increasing molecular knowledge about the conserved 
epitope in the stem of the HA protein will help to develop universal influenza vaccines directed to 
this epitope.  
Methods 
Viruses 
For preparation of viral stocks MDCK cells were infected at a multiplicity of infection (MOI) of 
0.001 and and the resulting viruses were harvested 48 to 76 hours after infection. Alternatively, em-
bryonated hen eggs were inoculated with titrated amounts of virus and incubated for 48h at 37°C 
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before the allantoic liquid was harvested. Virus-containing supernatant or allantoic liquid was stored 
in aliquots at -70°C.  
Reassortant viruses 
If not available, HA genes of interest were amplified and cloned into pHW2000 as described by 
Hoffman et al. [31] For the generation of reassortant viruses, a pHW2000-derived plasmid containing 
segment 4 was mixed with plasmids containing the remaining 7 genome segments from A/Puerto 
Rico/8/1934(H1N1), and transfected into a mixture of 293T and MDCK cells as described by [32]. 
Three days after transfection, presence of virus was determined by hemagglutination and clarified 
supernatant was used to infect MDCK cells. Three days later, P1 supernatant was harvested and fro-
zen at -70°C 
Library construction and phage display selection of cross-reactive Fab clones 
The antibody phage display library was prepared according to Barbas et al. [33]. In brief, donor 
13 (RI-13), a healthy Caucasian male of 32 years was selected for this study due to slightly elevated 
titers against recombinant H5 protein in a preliminary screening ELISA. According to the question-
naire filled at the time of the blood draft, donor 13 had been vaccinated 6 times against seasonal 
influenza, had not knowingly been exposed to avian influenza A viruses, and did not experience an 
influenza episode or vaccination during the 3 months prior to the blood donation (April 4th 2009). 
Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll density-cushion centrifugation on 
the day of the draft, and cells were cryopreserved in aliquots of 2x107 PBMCs for later use. 
At the day of the library preparation, ~1.6x106 mature B cells were isolated from thawed 
PBMCs using anti CD22-coated MACS beads (Milteny Biotech) according to the manufacturer’s in-
structions. Total RNA was isolated from B cells using RNeasy Mini Kit columns (Qiagen) and was re-
verse transcribed into cDNA using Superscript II reverse transcriptase from Invitrogen and oligo dT 
primers (Promega) according to the manufacturer’s recommendations. Immunoglobulin variable 
regions were PCR amplified from this cDNA, and assembled into Fab fragments in 3 subsequent PC 
reactions according to [33]. Ligation of the assembled Fab fragments into the pComb3X phage display 
vector yielded 1.5x109 plasmid clones that gave rise to more than 1013 plaque forming units after 
super-infection with a helper phage.  
For the panning, biotinylated and trypsin-digested hemagglutinin from A/Japan/1957(H2N2) 
was immobilized on streptavidin coated magnetic beads (Promega). Approximately 2.5x1012 of phag-
Results 
 
57 
 
es were combined with 15µg of HA immobilized on 300 µl magnetic beads (final concentration of 
immobilized HA was 100 nM) for the first round of selection. A total of 4 panning rounds were con-
ducted with increasing the stringency by using less protein-coated beads (2 µg of HA immobilized on 
50 µl magnetic beads) and increasing the number of washes (1st round: 2x TBST; 2nd round: 4x TBST, 
1xTBS; 3rd round: 6x TBST, 1xTBS; 4th round: 8xTBST, 1xTBS; TBST corresponds to TBS supplemented 
with 0.05% Tween 20). Phage clones obtained after the 3rd and 4th round were screened for binding 
to various HAs in ELISA, and positive clones were sequenced. One clone, referred to 3.1 was chosen 
for further analysis based on its sequence and binding properties.  
Expression and purification of recombinant HAs 
Recombinant HA, stabilized by a his-tagged trimerization domain, was expressed into the su-
pernatant of baculovirus-infected SF9 insect cells as previously described [34]. After 4 days, superna-
tant was harvested and soluble protein purified by metal affinity chromatography (NiNTA columns, 
GE Healthcare). Purified HA was proteolytically processed into its HA1 and HA2 subunits using 10U of 
TPCK-treated trypsin (from bovine pancrease, Sigma Aldrich) per 1 µg of HA for 1h at RT. Following 
digestion, trypsin was removed by size exclusion chromatography using a 200ml Superdex® S200 gel 
filtration column (GE Healthcare). For further experiments, only the fraction corresponding to the HA 
trimer was used. 
Expression and purification of recombinant Fab or IgG1 molecules. 
For the purification of Fab 3.1 the protocol by Barbas et al. was followed [33]. Briefly, the 
phagemid containing the 3.1 sequence was transformed into chemically competent TOP 10 E. coli 
cells (Invitrogen). A single colony from the transformation plate was inoculated into LB supplemented 
with carbenicilin (50 µg/ml), and grown under agitation (200 rpm) at 37⁰C over night. This pre-culture 
was then diluted 1:100 in SB supplemented with carbenicilin (50 µg/ml) and 20 mM MgCl2, and was 
grown under agitation (250 rpm) at 37⁰C for 24h. Bacterial cells were harvested by centrifugation 
and disrupted using a sonicator (Branson Sonifier 250). Lysate was cleared by centrifugation (>13500 
rpm for 60min) and filtration at 0.2 µm, and Fab fragments isolated by affinity chromatography using 
protein G slury (GE healthcare). Bound Fab was eluted from the column using 0.1 M glycine pH 3, and 
stored in PBS at 4°C after buffer exchange. 
For expression of soluble IgG 3.1, FI6 and FI6-3.1 hybrid the variable regions of heavy and light 
chains were cloned into the corresponding pIg-Abvec plasmids [35]. Proteins were expressed by tran-
sient transfection of 293T cells (30 µg of each plasmid combined with 120 µg PEI per 1 T150 flask). 
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Cell supernatant was harvested, spinned down first at 3000 rpm 5 min and next at 8000 rpm 10 min, 
filtered at 0.2 µM, and recombinant IgG1 was purified by affinity chromatography using protein G 
columns. Eluted IgG1 was re-buffered into PBS and stored at 4°C. 
ELISA 
Binding of IgG 3.1, FI6 and FI6-3.1 to recombinant HA proteins (non trypsin digested H1 from 
A/Puerto Rico/8/34 (H1N1) and H7 from A/FPV/Bratislava/79 (H7N7), trypsin-digested and non-
digested H3 from A/Moscow/10/99 (H3N2), and trypsin-digested H12 from A/Duck/Alberta/60/76 
(H12N5) was detected by ELISA. To this end, half-area, high binding capacity plates (Costar) were 
coated with 25 μl/well of 2 μg/ml HA in PBS at 4 ⁰C over night. Plates were then blocked with 2% milk 
in PBS. IgG were titrated in 0.2% milk PBS, transferred to the blocked ELISA plates, and allowed to 
bind for 1 h. After washing with TBST (0.1% Tween), bound Ig was detected using a goat anti-human 
kappa-HRP secondary antibody (Southern Biotech) and developed using TMB as a substrate. As a 
negative control, HIV gp120-specific and 293T-cell expressed mAb b12 antibody was used  
Neutralization of Influenza A viruses 
Titrated amounts of IgG 3.1, or IgG1-b12 as negative control, were mixed in triplicates with a 
fixed amount of Influenza A virus corresponding to MOI 2-3 (~ 105 pfu) in DMEM medium supple-
mented with 0.2% BSA, 20 mM HEPES, 50U/ml penicillin and 50µg/ml streptomycin (DMEM/BSA). 
After incubation at 37⁰C/5% CO2 for 2h, the mAb-virus mixture was transferred to PBS washed, sub-
confluent MDCK cells seeded into 96-well tissue culture plates the day before (1.5x102 cells/ well, 
TPP), and incubated at 37⁰C/5% CO2 for 1h to allow infection. Residual virus and antibody was aspi-
rated, cells washed with PBS, and DMEM/BSA was added. Following incubation at 37°C/5% CO2 for 
4.5 to 7h (depending on the growth kinetics of the virus isolate), cells were fixed with methanol, 
washed and stained with a 3 µg/ml FITC-labeled antibody to influenza NP (ATCC HB-65™) in PBS con-
taining 1% BSA at 4°C over night. After washing the FITC-labeled antibody, cells were stained with 
DAPI to control for cell density or cell loss. The corresponding fluorescence was then measured in 
each well at 16 (FITC) and 9 (DAPI) distinct locations points in a Perkin Elmer plate reader. For each 
well, the average for all individual fluorescence measuring points was calculated and used for further 
analysis. EC50 values were determined in Prism 5 (GraphPad Software) using iterative computing of 
the best fitting Hill equation. 
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Infectivity reduction assay 
40 µl of DMEM/BSA containing 60 µg/ml of the antibody of interest were mixed with 80µl of 
untitrated virus supernatant and incubated for 90min at 37°C/CO2. As a control, the same amount of 
virus was mock-incubated with DMEM/BSA without antibody. Following incubation for 90min at 37°/ 
CO2, non-neutralized infectivity was determined by serial diluting the virus/antibody mixture 1 in 2, 
and infection of 2-4x104 MDCK cells with this dilution series. Infection was allowed to proceed 5-6 
hours before cells were fixed and stained with a FITC-labeled antibody to NP, as described above. 
Structural homology search 
To identify the closest structural homologs of mAb 3.1, the coordinates for the 3.1 antibody 
heavy and light chain was extracted from the structure of the complex and submitted to the PDBe 
(http://www.ebi.ac.uk/msd-srv/ssm/ssmstart.html) or DALI 
(http://ekhidna.biocenter.helsinki.fi/dali_server/ ) structural homology search engines as a pdb file.  
Kd Determination 
Kd values were determined by bio-layer interferometry (BLI) using an Octet Red instrument 
(ForteBio, Inc.) as described in [19]. Biotinylated HAs were used for these measurements. HAs at ~10-
50 µg/mL in 1X kinetics buffer (1X PBS, pH 7.4, 0.01% BSA, and 0.002% Tween 20) were loaded onto 
streptavidin-coated biosensors and incubated with varying concentrations of mAb3.1 Fab. If no initial 
binding was observed using the above conditions, mAb3.1 concentrations up to 1uM were used to 
detect whether changes could be observed in the binding curves. 
Crystallization and structure determination of Fab3.1-Sc1918/H1 HA 
For Fab/HA complex formation, mAb3.1 Fab was added to Sc1918/H1 HA in a molar ratio of 
~3.2:1 to saturate all of the mAb3.1 binding sites on the HA trimer. The mixture was incubated over-
night at 4°C to allow complex formation. Saturated complexes were then purified from unbound Fab 
by gel filtration and concentrated to ~10 mg/mL in 10mM Tris-HCl, pH 8.0 and 50 mM NaCl. Fab3.1-
Sc1918/H1 HA crystals were grown by sitting drop vapor diffusion at 20°C by mixing 0.5 µL of concen-
trated protein sample with 0.5 µL of mother liquor (15% PEG 3350, 0.1M sulfate de Magnesium, 
100mM Tris-HCl pH7.5) and crystals appeared after 3 days. The resulting crystals were cryoprotected 
by soaking the crystals in well solution supplemented with increasing concentrations of ethylene 
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glycol (5% steps, 5 min/step), to a final concentration of 35%, then flash cooled and stored in liquid 
nitrogen.  
Diffraction data were collected at the Canadian Light Source (CLS). The data were indexed in 
space group R3, scaled and integrated using Denzo and Scalepack through the HKL2000 package (HKL 
Research). Detailed data collection and refinement statistics are summarized in Supplementary Table 
4. The structure was solved by molecular replacement to 2.9 Å resolution using Phaser [36]. Rigid 
body refinement, simulated annealing and restrained refinement (including TLS refinement, one for 
each Ig domain) were carried out in Refmac [37]. Between rounds of refinement, the model was re-
built and adjusted using Coot [38]. 
Crystallization and structure determination of mAb3.1 Fab 
The methods used to determine the mAb3.1 Fab structure were very similar to those described 
above. Briefly, mAb3.1 Fab at 15 mg/ml in 10mM Tris, pH 8.0 and 50 mM NaCl was subjected, after 
gel filtration, to robotic crystallization trials using the Rigaku Crystalmation robotic system at the 
Joint Center for Structural Genomics (JCSG). Several hits were obtained. The crystals used for data 
collection were grown by the sitting drop vapor diffusion method with a reservoir solution (1 mL) 
containing 0.2 M calcium acetate, 10% PEG 8000 and 100 mM Tris pH7.0. The resulting crystals were 
cryoprotected by soaking in well solution supplemented with 35% ethylene glycol, then flash cooled 
and stored in liquid nitrogen until data collection.  
The mAb3.1 dataset was collected to 2.7 Å resolution at APS GM/CA-CAT 23ID-B beamline. De-
tailed data collection and refinement statistics are summarized in Supplementary Table 4. The struc-
ture was solved using the same strategies as described for the Fab3.1-Sc1918/H1 complex. 
Structural analysis 
Hydrogen bonds and van der Waals’ contacts between mAB3.1 Fab and Sc1918/H1 HA were 
calculated using HBPLUS and CONTACSYM, respectively [39, 40]. Surface area buried upon Fab bind-
ing was calculated with MS [41]. MacPyMol (DeLano Scientific) was used to render structure figures 
and for general manipulations. Kabat numbering was applied to the coordinates using the Abnum 
server [42]. The final coordinates were validated using the JCSG quality control server (v2.7), which 
includes Molprobity [43].  
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Figures 
  
Figure 1: Virus neutralizing activity of mAb 3.1 
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Figure 2: Neutralization sensitivity of wt and reassorted A/Puerto Rico/8/1934(H1N1) carrying wt or mutant 
H11 hemagglutinin from A/duck/Memphis/546/1974 (H11N9). To remove glycosylation at position 291, aa 293 
was mutated from threonine to alanine (deglyco 291) or prolin (pro 293). The reciprocal mutations have been 
introduced into H1 as indicated in the table.  
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Figure 3: In vivo protection by passive immunization with mAb 3.1. The indicated dose of mAb or PBS were 
injected i.p. 24h before intranasal infection with 2xLD50 of A/Puerto Rico/8/34(H1N1). Body weight was moni-
tored and mice were taken out of the experiment when their weight dropped below 80% of the initial body 
weight. Data shown were pooled from two independent experiments.  
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C 
 
Figure 4: Crystal structure of Fab 3.1 bound to HA from A/South Carolina/1/1918(H1N1) (A) Overview of the 
antibody binding to the conserved epitope in the stem of the HA protein. (B) Comparison of epitope recogni-
tion of Fab 3.1 with mAbs FI6 and C179, as well as artificially binding proteins HB38, and F-HB80.4. The interact-
ing residues on HA1 were colored light brown and on HA2 violet. (C) Comparison of CDRH1 free (gray) and in 
complex with HA from A/South Carolina/1/1918(H1N1). 
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Supplementary Tables 
mAb VH DH JH CDR3H VL JL CDR3L 
3.1 IGHV3-30*04 IGHD3-9*01 IGHJ4*01, or 
IGHJ4*03 
CARDLGGYFIRGIMDVW IGKV1-12*01, or 
IGKV1-12*02 or 
IGKV1D-12*02 
IGKJ4*01 CQQANSFPLTF 
3.2 IGHV3-30*04 IGHD3-9*01 IGHJ4*01, or 
IGHJ4*03 
CARDLGGYFIRGIMDVW IGLV2-14*01 IGLJ3*02 CSSHTSSSTWVF 
3.4 IGHV3-30*04 IGHD3-9*01 IGHJ4*01, or 
IGHJ4*03 
CARDLGGYFIRGIMDVW IGLV6-57*01 IGLJ7*01 CQSYDNLNHAVF 
3.5 IGHV3-30*04 IGHD3-9*01 IGHJ4*01, or 
IGHJ4*03 
CARDLGGYFIRGIMDVW IGKV3-20*01 IGKJ1*01 CQQYGSSPRTF 
3.7 IGHV3-30*04 IGHD3-9*01 IGHJ4*01, or 
IGHJ4*03 
CARDLGGYFIRGIMDVW IGLV3-21*01 IGLJ2*01, or 
IGLJ3*01 
CQVWDSHGDQVVF 
3.8 IGHV3-30*04 IGHD3-9*01 IGHJ4*01, or 
IGHJ4*03 
CARDLGGYFIRGIMDVW IGKV3-11*01 IGKJ3*01 CQQRSNWPVTF 
3.9 IGHV3-30*04 IGHD3-9*01 IGHJ4*01, or 
IGHJ4*03 
CARDLGGYFIRGIMDVW IGLV1-44*01 n.a. n.a. 
3.10 IGHV3-30*04 IGHD3-9*01 IGHJ4*01, or 
IGHJ4*03 
CARDLGGYFIRGIMDVW IGKV3-20*01 IGKJ1*01 CQHYGASPKTF 
3.11 IGHV3-30*04 IGHD3-9*01 IGHJ4*01, or 
IGHJ4*03 
CARDLGGYFIRGIMDVW IGLV1-44*01 IGLJ3*02 CSSWDGGLSDWVF 
3.12 IGHV3-30*04 IGHD3-9*01 IGHJ4*01, or 
IGHJ4*03 
CARDLGGYFIRGIMDVW IGKV3D-20*01 IGKJ1*01 CQQYGSSPQTF 
3.13 IGHV3-30*04 IGHD3-9*01 IGHJ4*01, or 
IGHJ4*03 
CARDLGGYFIRGIMDVW IGKV1-33*01, or 
IGKV1D-33*01 
IGKJ4*01 CQQHDNLPLTF 
3.14 IGHV3-30*04 IGHD3-9*01 IGHJ4*01, or 
IGHJ4*03 
CARDLGGYFIRGIMDVW IGKV3-20*01 IGKJ2*01 CQQYGGSPPYTF 
3.15 IGHV3-30*04 IGHD3-9*01 IGHJ4*01, or 
IGHJ4*03 
CARDLGGYFIRGIMDVW IGLV6-57*01 IGLJ3*02 CQSYDSSNQWVF 
3.16 IGHV3-30*04 IGHD3-9*01 IGHJ4*01, or 
IGHJ4*03 
CARDLGGYFIRGIMDVW IGLV2-14*01 IGLJ2*01, or 
IGLJ3*01 
CSSYTSSSTVVF 
3.17 IGHV3-30*04 IGHD3-9*01 IGHJ4*01, or 
IGHJ4*03 
CARDLGGYFIRGIMDVW IGKV3-20*01 IGKJ4*01 CQQYGSSPLTF 
3.18 IGHV3-30*04 IGHD3-9*01 IGHJ4*01, or 
IGHJ4*03 
CARDLGGYFIRGIMDVW IGLV2-14*01 IGLJ2*01, or 
IGLJ3*01 
CSSYTSSSTVVF 
3.48 IGHV3-30*04 IGHD3-9*01 IGHJ4*01, or 
IGHJ4*03 
CARDLGGYFIRGIMDVW IGKV3-20*01 IGKJ1*01 CQQYGSSPRTF 
FI6 IGHV3-30*03 F, 
or IGHV3-30*18 F 
IGHD3-9*01 IGHJ4*02 CAKDSQLRSLLYFEWLSQGYFDPW IGKV4-1*01 IGKJ1*01 CQQHYRTPPTF 
 
Suppl. Table 1: Genetic hallmarks of the antibodies isolated by panning a phage display library against recombi-
nant H2 protein, and FI6 for reference. Assignment of the germline genes and CDRs were performed using the 
vquest tools provided at IMGT (http://imgt.org/IMGT_vquest/vquest?livret=0&Option=humanIg) 
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Grp Sub-
type 
Strain Muta-
tion 
Kd (nM) HA1 HA2 
     38 40 41 42 289 290 291 292 293 318 18 19 20 21 38 41 42 45 46 48 49 52 53 56 
1 H1N1 A/South Carolina/1/1918 wt 1 H V N L N S S L P T I D G W Q T Q I D I T V N I 
1 H1N1 A/duck/Alberta/345/1976 wt 1 H V N L N S S L P I I D G W Q T Q I D I T V N I 
1 H1N1 A/USSR/90/1977 wt 2.2 H V N L N S S L P T I D G W Q T Q I N I T V N I 
1 H1N1 A/Beijing/262/1995 wt 0.9 H V N L N S S L P T M D G W Q T Q I N I T V N I 
1 H1N1 A/Solomon Islands/3/2006 wt 2.8 H V N L N S S L P T V D G W Q T Q I N I T V N I 
1 H2N2 A/Japan/305/1957 wt 9.9 H K D I N T T L P T V D G W K T Q F D I T V N I 
1 H2N2 A/Adachi/2/1957 wt 10 H K D I N T T L P T V D G W K T Q F D I T V N I 
1 H5N1 A/Vietnam/1203/2004 wt 2 H Q D I N S D M P T V D G W K T Q I D V T V N I 
1 H6N2 A/turkey/Massachusetts/3740/19
65 
wt 25 H V E L K T N K T T I D G W K T Q I D I T V N I 
1 H12N5 A/duck/Alberta/60/1976  N.B Q E  L   S K P T V A G W R T Q I D   L  I 
1 H13N6 A/gull/Maryland/704/1977  N.B S I  L   N R T T I N G W K T Q I D   I  I 
1 H16N3 A/black-headed gull/Sweden/4/99  N.B S I  L   N K T T I N G W K T Q I N   I  I 
2 H3N8 A/duck/Ukraine/1/1963  N.B N T  L   D K P T I D G W L T Q I D   L  I 
2 H3N2 A/Hong Kong/1/1968  N.B N T  L   D K P T I D G W L T Q I D   L  I 
2 H4N6 A/duck/Czechoslovakia/1956  N.B T Q  L   T K P T I D G W L T Q I D   L  I 
2 H7N7 A/Netherlands/219/2003  N.B N T  T   N L P T I D G W Y T Q I D   L  I 
2 H10N7 A/chicken/Germany/N/1949  N.B N T  T   K L P T V D G W Y T Q I D   L  I 
2 H14N5 A/mallard/Astrakhan/263/1982  N.B S K  L   D K P T I D G W L T Q I D   L  I 
2 H15N9 A/shearwater/W. Austral-
ia/2576/79 
 N.B N T  T   P L P L I D G W Y T Q I D   L  I 
Suppl. Table 2: Binding of Fab 3.1 to HA from the indicated subtype. N.B.- Not Binding.  
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type of inter-
action 
Chain Residue Res. # Atom Chain Residue Res. # Atom # of int. Dist. 
VDW HA1 HIS 38 CB heavy TYR 99 OH 1 3.56 
VDW HA1 HIS 38 CB heavy TYR 99 CZ 1 3.58 
VDW HA1 HIS 38 CB heavy TYR 99 CE1 1 3.9 
VDW HA1 HIS 38 CB heavy TYR 99 CE2 1 4.02 
VDW HA1 HIS 38 CG heavy TYR 99 CZ 1 3.94 
VDW HA1 HIS 38 CG heavy TYR 99 CE1 1 3.97 
VDW HA1 HIS 38 ND1 heavy TYR 52A OH 1 3.52 
VDW HA1 HIS 38 ND1 heavy TYR 99 CD2 1 3.74 
VDW HA1 HIS 38 ND1 heavy TYR 99 CE2 1 3.83 
VDW HA1 HIS 38 CE1 heavy TYR 52A OH 1 3.73 
VDW HA1 HIS 38 CE1 heavy TYR 99 CG 1 4.1 
VDW HA1 VAL 40 CB heavy PHE 27 CE2 1 3.63 
VDW HA1 VAL 40 CB heavy PHE 27 CZ 1 3.96 
VDW HA1 VAL 40 CG1 heavy PHE 27 CE2 1 3.94 
VDW HA1 VAL 40 CG1 heavy MET 31 CG 1 4 
VDW HA1 VAL 40 CG1 heavy MET 31 SD 1 4.15 
VDW HA1 VAL 40 CG2 heavy PHE 27 CE2 1 3.91 
VDW HA1 ASN 41 O heavy PHE 27 CZ 1 3.33 
VDW HA1 ASN 41 O heavy PHE 27 CE1 1 3.73 
VDW HA1 LEU 42 CD2 heavy PHE 27 CZ 1 3.77 
VDW HA1 LEU 42 CD2 heavy PHE 27 CE2 1 3.9 
SHORTVDW HA1 ASN 289 OD1 heavy MET 75 SD 1 3 
VDW HA1 ASN 289 OD1 heavy MET 75 CG 1 3.81 
VDW HA1 SER 290 N heavy MET 75 CE 1 3.96 
VDW HA1 SER 290 CA heavy MET 75 CE 1 3.99 
VDW HA1 SER 290 C heavy MET 75 CE 1 3.71 
VDW HA1 SER 290 O heavy MET 75 CE 1 3.88 
H-BOND HA1 SER 291 N heavy SER 74 O 1 3.03 
VDW HA1 SER 291 CA heavy SER 74 O 1 3.65 
SHORTVDW HA1 SER 291 CB heavy SER 74 O 1 3.1 
VDW HA1 SER 291 CB heavy ARG 30 NH2 1 3.69 
VDW HA1 SER 291 CB heavy ASN 76 CB 1 3.86 
H-BOND HA1 SER 291 OG heavy SER 74 O 1 2.93 
H-BOND HA1 SER 291 OG heavy MET 75 O 1 3.12 
VDW HA1 SER 291 OG heavy MET 75 C 1 3.12 
VDW HA1 SER 291 OG heavy ASN 76 CB 1 3.37 
VDW HA1 SER 291 OG heavy MET 75 CE 1 3.37 
VDW HA1 SER 291 OG heavy MET 75 CA 1 3.51 
VDW HA1 SER 291 OG heavy ASN 76 N 1 3.58 
VDW HA1 SER 291 OG heavy SER 74 C 1 3.88 
VDW HA1 LEU 292 CD2 heavy ARG 30 NH2 1 3.48 
VDW HA1 LEU 292 CD2 heavy PHE 27 CE1 1 3.64 
VDW HA1 PRO 293 CD heavy PHE 27 CE1 1 3.9 
VDW HA1 PRO 293 CD heavy PHE 27 CD1 1 3.97 
VDW HA1 THR 318 CB heavy TYR 99 OH 1 3.43 
H-BOND HA1 THR 318 OG1 heavy TYR 99 OH 1 2.63 
VDW HA1 THR 318 OG1 heavy TYR 99 CZ 1 3.6 
VDW HA1 THR 318 OG1 heavy TYR 99 CE1 1 3.87 
VDW HA1 THR 318 CG2 heavy TYR 99 OH 1 3.88 
VDW HA1 THR 318 CG2 heavy MET 31 CE 1 4.01 
VDW HA1 THR 318 CG2 heavy MET 31 SD 1 4.04 
VDW HA2 ILE 18 O heavy PHE 100 CD1 1 3.46 
VDW HA2 ILE 18 O heavy PHE 100 CE1 1 3.56 
VDW HA2 ASP 19 C heavy PHE 100 CD1 1 3.67 
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VDW HA2 ASP 19 O heavy PHE 100 CB 1 3.65 
VDW HA2 ASP 19 O heavy PHE 100 CG 1 3.74 
VDW HA2 ASP 19 O heavy PHE 100 CD1 1 3.81 
VDW HA2 GLY 20 N heavy PHE 100 CD1 1 3.55 
VDW HA2 GLY 20 N heavy PHE 100 CE1 1 3.69 
VDW HA2 GLY 20 CA heavy PHE 100 CE1 1 3.68 
VDW HA2 GLY 20 CA heavy PHE 100 CD1 1 3.7 
VDW HA2 GLY 20 CA heavy PHE 100 CZ 1 3.83 
VDW HA2 GLY 20 CA heavy PHE 100 CG 1 3.85 
VDW HA2 GLY 20 CA heavy PHE 100 CE2 1 3.99 
VDW HA2 GLY 20 CA heavy PHE 100 CD2 1 4.01 
VDW HA2 GLY 20 C heavy PHE 100 CZ 1 3.59 
VDW HA2 GLY 20 C heavy PHE 100 CE1 1 3.79 
VDW HA2 GLY 20 C heavy PHE 100 CE2 1 3.96 
VDW HA2 GLY 20 O heavy PHE 100 CZ 1 3.76 
VDW HA2 GLY 20 O heavy PHE 100 CE1 1 3.79 
VDW HA2 TRP 21 N heavy PHE 100 CZ 1 3.9 
VDW HA2 TRP 21 CG heavy PHE 100 CE2 1 3.85 
VDW HA2 TRP 21 CG heavy PHE 100 CZ 1 4 
VDW HA2 TRP 21 CD1 heavy PHE 100 CZ 1 3.53 
VDW HA2 TRP 21 CD1 heavy PHE 100 CE2 1 3.79 
VDW HA2 TRP 21 NE1 heavy PHE 100 CZ 1 3.72 
VDW HA2 TRP 21 NE1 heavy PHE 100 CE2 1 3.86 
VDW HA2 TRP 21 CE2 heavy PHE 100 CE2 1 3.96 
VDW HA2 TRP 21 CD2 heavy PHE 100 CE2 1 3.95 
VDW HA2 TRP 21 CH2 heavy TYR 99 CE1 1 4.12 
VDW HA2 TRP 21 CH2 heavy TYR 99 CD1 1 4.17 
VDW HA2 TRP 21 CZ2 heavy TYR 99 CD1 1 3.66 
VDW HA2 TRP 21 CZ2 heavy TYR 99 CE1 1 3.69 
VDW HA2 GLN 38 CB heavy ARG 100B NH2 1 3.57 
VDW HA2 GLN 38 OE1 heavy ARG 100B NH1 1 3.6 
VDW HA2 GLN 38 OE1 light TRP 32 CH2 1 3.64 
VDW HA2 GLN 38 OE1 light TRP 32 CZ3 1 3.65 
VDW HA2 GLN 38 NE2 heavy ARG 100B CG 1 3.9 
VDW HA2 THR 41 CG2 heavy PHE 100 CD2 1 3.7 
VDW HA2 THR 41 CG2 heavy PHE 100 CE2 1 3.84 
VDW HA2 GLN 42 CD heavy LEU 96 O 1 3.65 
H-BOND HA2 GLN 42 OE1 heavy ARG 100B NE 1 2.96 
VDW HA2 GLN 42 OE1 heavy ARG 100B CD 1 3.35 
VDW HA2 GLN 42 OE1 heavy LEU 96 O 1 3.54 
VDW HA2 GLN 42 OE1 heavy GLY 97 CA 1 3.62 
H-BOND HA2 GLN 42 NE2 heavy LEU 96 O 1 3.08 
VDW HA2 ILE 45 CG1 heavy GLY 97 O 1 3.83 
VDW HA2 ILE 45 CD1 heavy PHE 100 CD2 1 3.7 
VDW HA2 ILE 45 CD1 heavy PHE 100 CE2 1 3.83 
VDW HA2 ILE 45 CG2 heavy GLY 97 O 1 3.91 
VDW HA2 ILE 45 CG2 heavy TYR 32 OH 1 4.03 
VDW HA2 THR 49 CA heavy THR 28 CG2 1 4.06 
VDW HA2 THR 49 CB heavy TYR 32 OH 1 3.55 
VDW HA2 THR 49 CB heavy THR 28 CG2 1 4.17 
H-BOND HA2 THR 49 OG1 heavy TYR 32 OH 1 3.22 
SHORTVDW HA2 THR 49 CG2 heavy TYR 32 OH 1 3.24 
SHORTVDW HA2 THR 49 CG2 heavy MET 31 CE 1 3.42 
VDW HA2 THR 49 CG2 heavy TYR 32 CE2 1 3.56 
VDW HA2 THR 49 CG2 heavy TYR 32 CZ 1 3.79 
VDW HA2 THR 49 CG2 heavy MET 31 SD 1 3.84 
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VDW HA2 THR 49 CG2 heavy THR 28 CB 1 3.93 
VDW HA2 THR 49 CG2 heavy THR 28 CG2 1 3.98 
VDW HA2 THR 49 C heavy THR 28 CG2 1 4.13 
VDW HA2 THR 49 O heavy THR 28 CG2 1 3.4 
VDW HA2 VAL 52 CB heavy THR 28 CG2 1 3.8 
VDW HA2 VAL 52 CG1 heavy THR 28 CG2 1 3.58 
VDW HA2 VAL 52 CG1 heavy PHE 27 CD2 1 3.97 
VDW HA2 ASN 53 CG heavy THR 28 OG1 1 3.26 
VDW HA2 ASN 53 CG heavy THR 28 CG2 1 3.45 
VDW HA2 ASN 53 CG heavy THR 28 CB 1 3.97 
H-BOND HA2 ASN 53 OD1 heavy THR 28 OG1 1 3.09 
SHORTVDW HA2 ASN 53 OD1 heavy THR 28 CG2 1 3.15 
VDW HA2 ASN 53 OD1 heavy THR 28 CB 1 3.63 
H-BOND HA2 ASN 53 ND2 heavy THR 28 OG1 1 2.72 
H-BOND HA2 ASN 53 ND2 heavy GLU 26 OE1 1 3.3 
VDW HA2 ASN 53 ND2 heavy THR 28 CG2 1 3.55 
VDW HA2 ASN 53 ND2 heavy THR 28 CB 1 3.69 
VDW HA2 ILE 56 CD1 heavy PHE 27 CD2 1 3.6 
VDW HA2 ILE 56 CD1 heavy PHE 27 CG 1 3.64 
VDW HA2 ILE 56 CD1 heavy PHE 27 CB 1 3.82 
VDW HA2 ILE 56 CD1 heavy PHE 27 CE2 1 4.21 
VDW HA2 ILE 56 CD1 heavy PHE 27 CD1 1 4.27 
Suppl. Table 3: Interactions of mAb 3.1 with HA from A/South Carolina/1/1918(H1N1). For graphic representa-
tion see Figure 4. 
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Data collection Fab 3.1 Fab 3.1- SC1918/H1 HA 
Beamline APS GM/CA CAT 23ID-B CLS 
Wavelength (Å) 0.71941 0.97549 
Space group P43 R3 
Unit cell parameters (Å, ) a =73.8, b =73.8,  
c = 207.9  
α=β=γ=90 
a =135.0, b =135.0,  
c = 230.2  
α=β=90, γ=120 
Resolution (Å) a 50 -2.7 (2.75- 2.70) 50-2.9 (2.95-2.9) 
Observations 118,373 196,824 
Unique reflections 30,297 (1515) a 34347 (1706) 
Redundancy 3.9 (3.8) a 5.7 (4.7) 
Completeness (%) 98.2 (98.7) a 99.6 (96.3) 
<I/sI> 12.2 (1.5) a 31.4 (2.1) 
Rsymb 0.12 (0.65) a, b 0.1 (0.72) 
Zac 4 1 
Refinement statistics   
Resolution (Å) 50-2.7 50-2.9 
Reflections (work) 28,423 32,610 
Reflections (test) 2,117 2,360 
Rcryst(%)d 22.8 19.3 
Rfree(%)e 27.3 24.1 
Average B-value (Å2) 39.0 90 
Protein atoms 6498 7222 
Carbohydrate atoms 0 0 
Waters 0 0 
RMSD from ideal geometry   
Bond length (Å) 0.011 0.012 
Bond angles (⁰) 1.49 1.48 
Ramachandran statistics (%)g   
Favored 93.1 90.43 
Outliers 2.3 1.63 
PDB ID XXXg XXX g 
a Numbers in parentheses refer to the highest resolution shell. 
b Rsym = hkl i | Ihkl,i  - <Ihkl> | / hkl i Ihkl,I and Rpim = hkl (1/(n-1))1/2 i | Ihkl,i  - <Ihkl> | / hkl i Ihkl,I, where Ihkl,i is the scaled 
intensity of the ith measurement of relection h, k, l, < Ihkl > is the average intensity for that reflection, and n is the redundancy 
(62).  
c Za is the number of either Fab, HA monomer or HA monomer-Fab complexes per crystallographic asymmetric unit.  
d Rcryst = hkl | Fo - Fc | / hkl | Fo | x 100 
e Rfree was calculated as for Rcryst, but on a test set comprising 5% of the data excluded from refinement. 
f Calculated using Molprobity (53) 
g Coordinates and structure factors are deposited in the PDB and are available immediately on publication. 
Suppl. Table 4: Data collection and refinement statistics. 
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4.2 A novel pan flu monoclonal antibody in functional comparison 
with other broadly cross-reactive, neutralizing mAbs recognizing 
a conserved epitope on Influenza A hemagglutinin 
This is a manuscript in preparation. I contributed in the following way: I prepared the phage 
display library by cloning the genetic material from isolated B cells; mutated, cloned, expressed, puri-
fied and biotinylated the H7 hemagglutinin used for panning; performed selection; expressed and 
purified mAb 1.12 and some of the hemagglutinins used for subsequent assays; purified most of the 
virus stocks; validated mAb 1.12 in binding, neutralization, epitope mapping and kinetic assays; per-
formed in vivo protection assays. I also prepared figures and wrote every part of the manuscript. 
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with other broadly cross-reactive, neutralizing mAbs recogniz-
ing a conserved epitope on Influenza A hemagglutinin 
 
Wyrzucki A1, Blattmann B3, Steck M1, Bianchi M1, Kohler I1, Grütter M3, Hangartner L1. 
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Summary 
Influenza A viruses can tolerate changes in their antigenic structures very well, and are capable 
of rapidly escaping pre-existing immunity. Here we describe a novel monoclonal antibody (clone 
1.12) selected from a human phage-display library that, in contrast to the majority of antibodies elic-
ited by vaccination or natural infection, has a broad neutralizing activity encompassing all 15 sub-
types tested. Competition assays using murine c179 antibody revealed that 1.12 interacts with a simi-
lar, conserved epitope in the stem of hemagglutinin. Kinetic experiments showed that virus neutrali-
zation by mAb 1.12 and two other heterosubtypic antibodies is irreversible. However, potent neutral-
ization is possible only if the antibodies bind to HA spikes before virus attaches to the cell surface. 
Furthermore, we did not find interference between HA-reactive human sera and heterosubtypic an-
tibodies, indicating that pre-existing immunity would not hamper the access of these antibodies to 
the membrane-proximal region of hemagglutinin. Accordingly, these data suggest that heterosubtyp-
ic antibodies are likely to be effective in influenza exposed individuals once elicited by a properly 
designed immunogen. 
Introduction 
Hemagglutinin (HA) and neuraminidase (NA), the two major surface antigens of Influenza A vi-
rus, rapidly change in a process known as antigenic drift [1]. This enables the virus to escape pre-
existing immunity causing seasonal epidemics and local outbreaks. Besides acquiring mutations, the 
HA and NA genome segments can also be exchanged between subtypes, leading to the emergence of 
new reassortant viruses. Viruses arising from this process known as antigenic shift have caused sev-
eral pandemics in the past with the 1918-1919 ‘Spanish flu’ outbreak being the most severe [2, 3]. As 
a preventive measure, influenza vaccines have been used for over 70 years now [1, 4, 5]. Although 
quite effective against seasonal influenza, currently available vaccines have several limitations. One 
major drawback is that antibodies elicited by the seasonal vaccine only react with the inoculated and 
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closely related strains. This strain-specific (or homotypic) nature of the antibody response implies 
that seasonal vaccines have to be often reformulated to reflect antigenic changes acquired by drift-
ing. As an outcome, the vaccine manufacturing process is time consuming and the delivered vaccine 
may be ineffective if mismatch occurs. Therefore an extensive effort has been made in the last two 
decades to formulate an immunogen that would provide protection against multiple Influenza A sub-
types. Such vaccine would be beneficial not only during seasonal outbreaks but also against pandem-
ic strains that are insensitive to seasonal vaccination due to change of HA or NA subtype. 
The development of universal Influenza A vaccine has been approached over the years using 
several different strategies [6, 7]. One of the most promising is the elicitation of high titers of broadly 
cross-reactive antibodies to hemagglutinin (HA) [8-11]. HA is the major surface antigen of Influenza A 
and is crucial for virus entry into the host cell. There are currently 17 different subtypes of HA that 
are divided into two phylogenetic groups. The high immunogenicity of the protein makes HA an in-
teresting target for vaccine design. Multiple studies showed that antibodies elicited against HA are 
sufficient to provide protection from virus infection [12, 13]. However, as mentioned above, the 
cross-reactivity of induced sera is very limited. This arises from the fact that the majority of elicited 
antibodies bind the highly variable head of HA [14]. However, during last 20 years highly conserved 
epitopes could be identified on the Influenza A hemagglutinin, and their discovery is believed to facil-
itate the design of a universal Influenza A vaccine [15]. In the past 4 years several monoclonal anti-
bodies cross-reactive to many HA subtypes have been described [16-22]. However, of these only two 
mAbs, clones FI6 and CR9114, were binding the majority of HA subtypes from both phylogenetic 
groups. Detailed analysis revealed that all heterotypic antibodies react with HA stem, thus providing 
a structural basis for the design of a universal Influenza A vaccine. 
In this study we decided to broaden the knowledge about the binding properties of heterosub-
typic antibodies. We identified a novel heterosubtypic mAb, termed 1.12, from the antibody reper-
toire of a healthy donor using a phage display library and a modified HA antigen. Remarkably, clone 
1.12 neutralized multiple Influenza A virus strains belonging to HA subtypes 1 to 15. The viruses used 
in our neutralization assay were isolated over the last 80 years, which emphasizes the high conserva-
tion of the epitope recognized by mAb 1.12. As expected, binding competition assay revealed that 
1.12 interacts with HA stem with an epitope overlapping that previously described for stem-reactive 
mAb c179 [17, 23]. Furthermore, mAb 1.12 protected mice from lethal challenge with A/Puerto Ri-
co/8/1934 (H1N1) virus proving its in vivo efficacy. In addition, we showed that at least three het-
erosubtypic antibodies irreversibly neutralize the A/Puerto Rico/8/1934 (H1N1) virus, and their ac-
tion is not restricted in the presence of pre-existing serum antibodies binding to HA. Therefore our 
data suggest that HA stem-reactive, heterotypic mAbs can easily access their epitopes on intact virus 
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particles also in a situation when HA spikes are densely covered with strain-specific homotypic anti-
bodies. Thus we conclude that heterotypic antibodies elicited by a designed immunogen would be 
effective in protecting individuals that have already been exposed to Influenza A. 
Results 
Isolation of mAb 1.12 
We have used a Fab phage display library based on the quiescent B cell repertoire of a healthy 
human subject. The library has been panned against an immobilized and modified HA protein using 
standard procedure (see materials and methods for details). A single phage display selection with 4 
subsequent selection rounds was performed, and a total of 48 clones from the 3rd and 4th round were 
analyzed for ELISA binding to recombinantly expressed H2 (A/Japan/305/1957), H3 
(A/Moscow/10/1999) and H7 (A/ Fowl plague /Bratislava/1979) hemagglutinins. Remarkably, 43 out 
of 48 clones showed cross-reactivity to all tested HAs. Sequence analysis revealed that all selected 
clones have almost invariant heavy chains (HC) derived from the VH 1-69 germline. Interestingly, all 
positive clones have been identified with heavy chain complementarity determining region 3 
(HCDR3) that contains a long stretch of five adjacent tyrosine residues. In contrast, a high variability 
and the use of different germlines have been seen for light chains (LC). Thus we assumed that most 
possibly the heavy chain only is responsible for binding to HA, and randomly selected one clone 
termed 1.12.  
Binding and neutralizing activity of mAb 1.12 
To further analyze the cross-reactivity of clone 1.12, it was expressed as a soluble IgG1 mole-
cule in 293T cells. In ELISA, binding of a purified IgG1 to a panel of recombinant hemagglutinins from 
both phylogenetic groups was observed (Figure 1). mAb 1.12 bound all HAs (H1, H2, H3, H4, H5, H7, 
H12) with EC50 values ranging from 126 ng/ml to 979 ng/ml. The strongest binding was seen for the 
H1, the weakest for H12 hemagglutinin. Next, the neutralizing activity of mAb 1.12 was determined. 
A total of 19 Influenza A isolates from 15 HA subtypes was assessed. We deliberately chose life virus 
for these assays as pseudotyped viruses have been shown to be easier to neutralize [14]. We have 
found that mAb 1.12 neutralized all tested viruses at IC50 values ranging from 107 ng/ml to 23471 
ng/ml. No neutralization of an influenza B isolate was observed. Thus, mAb 1.12 neutralized all Influ-
enza A viruses tested and its epitope is obviously shared between at least 15 out of 17 HA subtypes 
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and has not been subject to antigenic drift since at least 1934, when the oldest strain tested was 
isolated.  
Epitope recognized by mAb 1.12 
Based on the structural data published for the previously described heterotypic antibodies 
binding HA we suspected that also mAb 1.12 is interacting with the HA stem [16-21, 23]. Indeed, in 
an ELISA binding competition assay using the prototypic stem-reactive mAb c179, c179 was outcom-
peted by mAb 1.12 in a concentration-dependent manner (Figure 2). Since no obvious structural 
changes in HA were found in the crystal upon binding of mAb C179 to hemagglutinin, it is safe to 
assume that the epitope of both antibodies overlap. Detailed structural and mutagenesis data are 
necessary to provide a solid proof for our findings. 
When the impact of glycosylation at position 291 and a proline at position 293 was assessed, it 
was found that the neutralizing activity of mAb 1.12 against a reassortant PR8 virus carrying the HA 
gene segment from A/duck/Memphis/546/74 (H11N9) in which the glycosylation site at position 291 
has been removed, it was about 10-fold more sensitive to neutralization by mAb1.12 than the glyco-
sylated wt HA protein (IC50 17.6 µg/ml vs. 2.4µg/ml).  
In vivo activity and pharmacokinetics of mAb 1.12 
We have evaluated the protective efficacy of mAb 1.12 in C57BL/6 mice in a prophylactic setup 
(Figure 3). To this end mice were injected IP with 10 or 3 mg/kg of mAb 1.12 24h before intra nasal 
infection with a 2xLD50 dose of A/Puerto Rico/8/1934 (H1N1) virus. At 10 mg/kg 8 out of 10 animals 
were protected whereas at 3 mg/kg only 1 out of 10 mice succumbed to infection. Furthermore, sur-
viving mice showed no apparent signs of morbidity and only displayed a moderate weight loss. Inter-
estingly, the time point of antibody application had an influence on protection by mAb 1.12. Intra 
peritoneal application 3h before infection conferred the lowest level of protection whereas intra 
venous injection 2h before infection was protective to all animals at both tested doses (15 and 5 
mg/kg, 3 mice per group). To further understand the aforementioned differences mice were injected 
intravenously with 5 or 15 mg/kg of mAb 1.12. Serum antibody levels were determined at different 
time points post injection. Based on the collected data we conclude that serum half-life of mAb 1.12 
is very satisfactory and the reported differences in level of protection can be most possibly attributed 
to slow diffusion of mAb 1.12 in tissues.  
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Functional comparison of mAbs 1.12, 3.1, FI6 
To gain insight into the functional and kinetic properties of HA-stem reactive antibodies, sev-
eral experiments were performed using a test panel of heterosubtypic mAbs: 1.12, 3.1, and FI6. First, 
to assess the reversibility of neutralization we preincubated A/Puerto Rico/8/1934 (H1N1) virus in 
solution with a fixed concentration of mAbs from our set (Figure 4). Next we captured the virus-mAb 
particles on magnetic beads and performed 3 different dissociation protocols: ‘no dissociation’ 
where captured virus is incubated in the presence of the antibody for 17 h, ‘short dissociation’ where 
antibodies were washed away just before adding the captured virus to cells and ‘long term dissocia-
tion’ where antibodies were washed away 14 h before the virus was added to cells. As depicted in 
Figure 4, even after prolonged dissociation time, virus neutralization was complete and thus indistin-
guishable from virus that was permanently incubated in the presence of the antibodies. Therefore 
we concluded that the heterosubtypic epitope is accessible on free virus particles in solution, and 
that neutralization of the infectivity is not reversible, either due to irreversible damage introduced to 
HA or due to little or no dissociation from the complex. 
In the 2nd assay, we tested whether heterosubtypic antibodies still have access to their epitope 
when virus particles are already bound to the cell surface (Figure 5). In two parallel setups we evalu-
ated the neutralizing activity of mAb 1.12, 3.1 and FI6 on the A/Puerto Rico/8/1934 (H1N1) as free 
virus in solution and virus already pre-adsorbed on cell surface. Surprisingly, neutralization of pre-
adsorbed virus on cell surface was much less efficient than that of free virions. This was seen for all 
tested mAbs suggesting that HA stem-reactive antibodies cannot effectively access their epitopes on 
hemagglutinin spikes once the virus is attached to cells. 
Since it has been speculated that apically binding strain-specific antibodies may sterically re-
strict access to the membrane-proximal heterosubtypic epitopes, we tested if antibodies from our 
panel can efficiently neutralize virus particles that have been saturated with human serum antibodies 
(Figure 6). To this end, A/Puerto Rico/8/1934 (H1N1) virus was incubated with human sera at con-
centrations that were subneutralizing but were confirmed to provide saturating binding to H1 PR8 
HA coated on ELISA plates. As a control, virus was mock incubated without serum. These virus prepa-
rations were then incubated with our panel of heterosubtypic mAbs at two limiting dilutions (10 and 
1 μg/ml). We have found that no difference between the applied setups can be seen. Thus, these 
data demonstrate that human serum antibodies do not interfere with neutralization of Influenza A 
virus by HA stem-reactive heterosubtypic mAbs. Furthermore, we could see an additive neutralizing 
effect when both serum and our mAbs have been applied at subneutralizing concentrations.  
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Discussion 
In this study we isolated a new pan-Influenza A antibody mAb 1.12 and evaluated its antiviral 
properties in comparison with two other heterotypic mAbs binding to the hemagglutinin stem. 
Broadly cross-reactive mAb 1.12 was isolated from a combinatorial phage display library that has 
been prepared from quiescent B-cells isolated from an average human individual. Since previous 
isolations of such antibodies typically involved brute-force approaches, we were reasonably surprised 
how easy it was to select multiple Fab clones with a very broad cross-reactivity to hemagglutinins 
from both phylogenetic groups of Influenza A in a single panning experiment [21]. This ease can be 
attributed to several factors. First, we used a modified hemagglutinin that was designed such that 
access of antibodies to the highly variable head was sterically impaired, while the conserved epitopes 
in the stem were prominently exposed. Second, we noticed that the antigen, whose design was 
based on the HA from phylogenetic group 2, selected heterotypic antibodies of broad specificity 
while the antigen based on an HA protein from phylogenetic group1 only isolated antibodies that are 
specific for strains from phylogenetic group 1. This indicates that the strain on which an antigen-
design is based may have a great impact on the antibodies selected. However, we are currently con-
ducting further studies to dissect the impact of either factor on the antibodies isolated in more de-
tail. Moreover, we are currently testing these antigens as immunogens in mice. 
mAb 1.12 showed remarkable cross-neutralizing activity to 15 out of 17 subtypes of Influenza 
A virus. Furthermore, clone 1.12 neutralized multiple isolates from each of the H1, H2, H3, H6 and H7 
subtypes. As the panel of viruses tested in our study represents almost 80 years of antigenic drift of 
Influenza A we conclude that the epitope recognized by antibody 1.12 is almost invariant across this 
genus. However, no apparent neutralization was seen for A/Shorebird/Delaware/172/06(H16N3) 
that also grew only very poorly in our hands. Since H16 is circulating in wild birds and up till now it 
was not identified in humans, we do not believe that this shortcoming is relevant for the potential 
use of this antibody as therapeutic agent. Moreover, similarly impressive breadth like that of clone 
1.12 has been previously only reported for Influenza A and B-specific antibody CR9114 [18]. Interest-
ingly, these antibodies share several features. First, they both recognize epitopes localized in HA 
stem. Second, they primarily utilize their heavy chains to bind hemagglutinin. Third, both have a 
stretch of at least four tyrosine residues in their HCDR3, that in case of CR9114 interact with the N-
terminal residues of HA2. 
Using 1.12 together with two other heterosubtypic mAbs, we have addressed several ques-
tions that are central for an estimation of the potential success of any vaccination eliciting het-
erosubtypic antibodies. It has been speculated that the tight arrangement of the HA and NA spikes 
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on the virion surface may make access to the membrane proximal heterosubtypic epitopes difficult. 
Moreover, this access may even be further restricted if the virions are saturated with homotypic 
antibodies, binding to the strain-specific apical epitopes, elicited during previous infections or vac-
cinations. However, we did not find that homotypic, serum antibodies interacting with hemagglutinin 
head interfere with the neutralizing activity of heterosubtypic antibodies. Accordingly, we do not 
predict that a universal influenza vaccine or therapy based on stem-reactive, heterotypic antibodies 
would be impaired by the presence of pre-existing strain-specific humoral immunity. 
When we assessed the reversibility of the neutralization by our set of heterosubtypic mAbs, 
we have found that at least H1N1 viruses are neutralized irreversibly. At this point we can only 
speculate about the reason for this irreversibility. One possibility would be that the stem reactive 
antibodies have a very slow dissociation rate thus, once bound to HA, they stay attached to it over a 
long period of time. Alternatively, prolonged binding of these antibodies may induce conformational 
changes that render the HA protein non-functional. Such mechanism of neutralization has been seen 
for the aforementioned gp120-specific mAbs [24]. Further investigation would be necessary to de-
scribe the neutralization mechanism in details. 
Quite unexpectedly, we did find that heterosubtypic antibodies cannot efficiently neutralize vi-
rus particles that are already attached to the cell surface. We speculate that based on the postulated 
aggregation of estimated six HA molecules required for fusion (three of which have to undergo a 
conformational change; [25]) a cluster of HA molecules is formed to whose center there is no access 
for heterosubtypic antibodies. Accordingly, a sufficient number of HA spikes still can undergo the 
confirmation change to mediate infection. 
The discovery of a novel pan Influenza A antibody altogether with a detailed evaluation of 
binding mechanism of heterosubtypic mAbs provides further insight into the subject of conserved 
epitopes on hemagglutinin. The data collected in our study may be essential for the design of a new 
immunogen and furthermore justify the use of HA as valuable antigen in the preparation of a univer-
sal influenza vaccine. 
Materials and methods 
Library construction and phage display selection of cross-reactive Fab clones 
The phage library was prepared as described in [26]. In brief, frozen PBMCs from donor RI13 
were used to purify B cells using anti-CD22 coated MACS beads (~1.6x106 B cells isolated). Following 
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total RNA extraction (RNeasy Mini, Qiagen), reverse transcription into cDNA was performed using 
oligo dT primer (Promega) and Superscript II reverse transcriptase (Invitrogen) according to the man-
ufacturer’s recommendations. Rearranged variable gene segment families were amplified individual-
ly and modified for phage surface expression in 3 subsequent PC reactions. Resulting full-length Fab 
fragments were cloned into the pComb3X phage display vector, and used to rescue a phage library 
with a total of 1.5x109 transformants giving rise to 3.3x1011 phage particles/ml library titer. 
This phage display library was enriched for phages binding to the antigenically altered antigens 
immobilized on streptavidin coated magnetic beads (construction and biochemical characterization 
of these antigens will be reported elsewhere; beads were purchased form Promega). Approximately 
2.5x1012 of phages were combined with bead-immobilized hemagglutinin (see below, f.c. of protein= 
100 nM as counted for HA dimer) in the first round of selection. In total 4 rounds of selection were 
performed with 100 nM HA concentration (as counted for HA trimer in rounds 2-4) and increasing 
wash stringency (wash with TBST 0.05% Tween 20). Phage clones obtained from 3rd and 4th round 
were screened for binding to various HAs in ELISA experiment. Positive clones were sequenced. 
Expression and purification of recombinant HAs 
Recombinant HA was expressed in SF9 cells using baculovirus vectors as described by Stevens 
or Ekiert [27]. In brief, HA open reading frames were modified to contain an insect secretion se-
quence at the N-termial, and foldon trimerization instead of a transmembrane and intracellular do-
main at the C-terminal end. Secreted recombinant protein was purified from cell supernatant 4 days 
post infection on NiNTA columns (GE healthcare). To process recombinant HA protein into HA1 and 
HA2, it was trypsin digested using 10U of TPCK-treated trypsin (from bovine pancrease, Sigma Al-
drich) at 1 μg of HA, at RT for 1h. Immediately after trypsinization, protein was purified by size exclu-
sion chromatography on a S200 gel filtration column (GE healthcare). For further experiments only 
the fraction corresponding to HA trimer was used. All proteins used in phage display had Cys residue 
introduced at position 158 in the head region to enable biotinylation (with EZ-link HPDP biotin, 
Pierce) and coupling to streptavidin beads in upside-down orientation. The proteins were further 
processed as described in phage display panning section. 
Expression and purification of IgG1 
For expression of soluble IgG1 1.12, 3.1 and FI6, the sequence of HC and LC were cloned into 
pAbvec Ig plasmids [28, 29]. Proteins were expressed by transfecting 293T cells (30 μg of each HC and 
LC plasmids per 1 T150 flask) using PEI as transfection reagent. Cell supernatants were harvested, 
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sterile filtered at 0.2 µm before recombinant IgG1 was purified via affinity chromatography using 
protein G slurry (GE healthcare). The column eluted IgGs (with 100 mM glycine, pH 2,7) were rebuff-
ered to PBS by dialysis using Spectra/Por 1 membrane (Spectrumlab) or three rounds of buffer ex-
change on centrifugal filter (Amicon Ultra-15). 
ELISA 
Binding of IgG 1.12 to various HAs was assessed by ELISA. To this end, high binding, half-area 
plates (Costar) were coated with 25 μl/well of 2-4 μg/ml HA in PBS at 4 ⁰C overnight. Plates were 
then blocked with 60 µl of 2% low-fat dry milk in PBS for 1h at RT. Purified IgG was titrated in 0.2% 
milk PBS, and incubated in a volume of 30 µl on the coated plates at RT for 1h. Bound IgG was de-
tected using goat anti-human kappa-HRP secondary antibody (1:5000, Southern Biotech). Between 
each step, plates were washed 4 times with approx. 200 µl of TBST (0.1% Tween). ELISA signal was 
developed using ultra TMB substrate (Pierce) for 5-10 min before the reaction was stopped by the 
addition of 2N H2SO4. OD450 was measured in the Perkin Elmer plate reader. As negative control, 
recombinantly expressed HIV gp120-specific IgG1 b12 was included in all assays. 
Competition ELISA 
ELISA plates (half area, high binding, Costar) were coated with 25 μl/well of 2 μg/ml of H1 PR8 
HA in PBS at 4 ⁰C ON. Plates were then blocked with 60 µl of 2% milk in PBS at RT for 1h. Blocked 
plates were incubated with 30 μl of serially diluted (in PBS/0,2% milk) human IgG 1.12 at RT for 1h 
and washed 3x with TBST. Further, the plates were incubated at RT for 1h with the murine IgG c179 
diluted in PBS/0,2% milk at 1 μg/ml and washed 4x with TBST. Binding of IgG 1.12 and IgG c179 was 
detected in parallel using goat anti-human kappa-HRP polyclonal serum (Southern Biotech) or poly-
clonal rabbit anti-mouse-HRP serum (Dako), respectively. Signal was developed as described in the 
ELISA section. 
Neutralization of Influenza A viruses 
Titrated IgG 1.12 was mixed with a fixed amount of Influenza A virus corresponding to MOI 2-3 
(~100000 pfu/well) in DMEM medium supplemented with 0,2% BSA, 20 mM HEPES, P/S, Glu (D/B/H 
medium). After 2h at 37⁰C in cell culture incubator mAb-virus mixture was transferred on PBS 
washed, subconfluent MDCK cells growing on 96-well tissue culture plates (TPP). To enable infection 
cells were kept in 37⁰C CO2 incubator for 1h. Next, the mix was removed from cells that were later 
washed with PBS and supplemented with D/B/H medium. After 5-7h (depending on the growth kinet-
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ics of virus isolate) in 37⁰C CO2 incubator cells were fixed with methanol, washed and stained with 
HB65-FITC (mAb detecting Influenza A NP) diluted in 1% BSA PBS at 3 μg/ml, 4⁰C, ON. FITC fluores-
cence signal was detected using Perkin Elmer plate reader. The b12 gp120 HIV- specific antibody was 
used as negative control. 
Reversibility of neutralization 
Highly concentrated, sucrose-cushion purified stock of A/Puerto Rico/8/1934 (H1N1) virus was 
diluted 1:30 in 900 μl of D/B/H medium and mixed with 100 µl of mAb dilution in the same medium 
in a way that the final mAb concentration was 10 μg/mL. The mixture was incubated in CO2 incubator 
at 37°C for 2h. In the meantime 120 μL of 1:10 diluted magnetic beads coated with α-N1 neuramini-
dase antibody was blocked with 120 μL of 2% milk in PBS at RT on rotator for 1h. After both incuba-
tion steps milk solution was removed, beads were washed with PBS, combined with the virus-mAb 
mixture and kept in CO2 incubator at 37°C on rotator for 1h. Next, 300 μL of the 1mL beads-virus-
mAb mixture was transferred into 3 tubes. From now on each tube represents one of the test condi-
tions: ‘no dissociation’, ‘short-term dissociation’ and ‘long-term dissociation’. Long-term dissociation 
beads were washed 1 x with 400 μL of D/B/H medium and resuspended in 1 ml of D/B/H medium 
without antibody. At the same time ‘no dissociation’ and ‘short-term dissociation’ tubes were filled 
up to 1 ml with D/B/H medium supplemented with appropriate mAb (final concentration 10 μg/ml). 
Next, tubes were kept in CO2 incubator at 37°C on rotator for 14 h. After incubation the supernatant 
was removed and 100 μL of D/B/H medium supplemented with 10 μg/mL of mAb added to ‘no disso-
ciation’ tube. In parallel the ‘short term dissociation’ and ‘long term dissociation’ samples were 
washed with D/B/H medium and resuspended in 100 μl of D/B/H medium. 50 μL of resuspended 
beads was next transferred on MDCK cells seeded at density 1-2e4/well in 96 well plate a day before. 
Plates with cells were kept in CO2 incubator at 37°C for 30 min, placed on orbital shaker for few sec 
to resuspend the beads and transferred back to incubator for another 30 min. After the incubation 
beads were again resuspended on orbital shaker, withdrawn and cells washed 1x with PBS. Further 
incubation and detection of infectivity was performed as described for neutralization assay. The HIV 
gp120-specific antibody b12 was used as non-neutralizing control. 
Neutralization of virus particles attached to cell surface 
MDCK cells were seeded with a number of 1-2x104/well a day before the experiment. At the 
day of experiment plates were transferred to fridge (4⁰C) for 15 min and later on ice for 15 min to 
ensure that no virus internalization will occur in the subsequent step. Next, cells were washed with 
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ice-cold PBS and infected at MOI~3 with A/Puerto Rico/8/1934 (H1N1) virus at 4⁰C for 1,5 h  (‘virus 
preadsorbed on cells’ plate). Another MDCK plate was prepared in parallel using the same procedure 
but no virus was added (‘virus in solution’ control sample). Both plates were next washed 1x with ice 
cold PBS. mAbs titrated in D/B/H medium were further added to ‘virus preadsorbed on cells’ plate. 
Ice cold D/B/H medium was added to the ‘virus in solution’ control plate. Next, both plates were 
incubated at 4⁰C for 2h. In parallel A/Puerto Rico/8/1934 (H1N1) virus (from the same initial dilution 
kept at 4⁰C) at MOI~3 was mixed with cold titrated mAbs on dilution plate and incubated at 4⁰C for 
2h. Further, both MDCK-containing plates were 1x washed with prewarmed PBS. ‘Virus preadsorbed 
on cells’ plate was covered with 100 µL of prewarmed D/B/H medium whereas the virus+mAb mix-
ture from titration plate was transferred to the ‘virus in solution’ control plate. Infectivity was later 
detected as described in the neutralization assay. The HIV gp120-specific antibody b12 was used as 
control. 
Competition with human sera 
20 μl of 1:405 diluted in D/B/H medium, concentrated, sucrose-cushion purified A/Puerto Ri-
co/8/1934 (H1N1) virus was first combined with 20 μl of appropriately diluted human serum and 
incubated in CO2 incubator at 37°C for 1h (final serum dilutions are indicated in table below). At this 
step 2 dilutions for each serum were used- the ‘optimal’ dilution which shows low neutralization and 
the ‘neutralizing’ dilution which provides suboptimal virus neutralization. Each dilution was con-
firmed beforehand to have a saturated binding to H1 PR8 recombinantly expressed HA in ELISA ex-
periment. After incubation 20 μl of appropriate mAb was added to virus-serum mix to a final concen-
tration of 10 or 1 μg/ml and the mixture was kept in CO2 incubator at 37°C for 1h. Next, 50 μl of the 
suspension was transferred on MDCK cells and incubated in CO2 atmosphere at 37°C for 1h to enable 
infection. Infectivity was later detected as described in the neutralization assay. 
Serum no Optimal dilution (1st) Neutralizing dilution (2nd) 
58 1:270 1:90 
75 1:100 1:33 
511 1:270 1:90 
579 1:270 1:90 
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Figures 
 
Figure 1. Binding and neutralizing activity of mAb 1.12. A) Phylogeny of Influenza A hemagglutinin. Two phylo-
genetic groups can be distinguished that encompass multiple clades that in turn split into individual subtypes. 
Phylogenetic group 1 is indicated in blue, group 2 in red. B) half-maximum binding (EC50) of mAb 1.12 to 7 
distinct HA subtypes was measured by ELISA. C) A panel of 20 viruses covering 16 subtypes of Influenza A has 
been tested for neutralization by mAb 1.12. The antibody concentration that neutralized 50% of the viral inocu-
lums (IC50) is indicated. HIV-1 gp120-specific mAb b12 was used as a negative control in both experiments. 
Values above 104(A) or 105(B) indicate no binding or neutralization, respectively. For subtype H16 no neutrali-
zation by mAb1.12 was seen. 
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Figure 2. Epitope mapping. A) The epitope recognized by mAb 1.12 was roughly evaluated in a binding compe-
tition ELISA assay using HA stem-reactive mAb C179. ELISA plates coated with purified HA from  A/Puerto Ri-
co/8/34(H1N1) was incubated with titrated amounts of mAb 1.12, washed and later incubated with a fixed 
concentration (1 μg/ml) of the murine mAb C179. Binding of both antibodies was next detected using different 
secondary polyclonal sera. B) The impact of glycosylation and presence of Pro residue in HA stem on activity of 
mAbs 1.12, 3.1 and FI6 was measured in a infectivity reduction assay using various Influenza A mutants and 
reassortant viruses. 
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Figure 3. Prophylactic protection of mice by mAb 1.12 A) Mice were injected intraperitoneally with the indi-
cated dose of mAb 1.12 in PBS or with PBS alone (control group) 24h prior to intranasal infection with a lethal 
dose of A/Puerto Rico/8/1934(H1N1) virus (2x103 TCID50 units). Mice dropping below 80% of initial body 
weight were scored as dead and euthanized. Each group contained 5 BL6 females, a representative of at least 2 
consistent experiments is shown. 
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Figure 4. Reversibility of Influenza A neutralization. Reversibility of neutralization has been tested as depicted 
in diagram (A). Three HA stem-reactive antibodies were incubated at concentration of 10 μg/ml with A/Puerto 
Rico/8/1934(H1N1) virus (amount corresponding to MOI ~ 30) and the mAb-virus mixture was captured on 
magnetic beads. Beads were then processed using different procedures mimicking ‘no dissociation’, ‘short 
dissociation’ and ‘long dissociation’ conditions. In the last step infectivity of each sample was measured in neu-
tralization assay with MDCK cells. The HIV-1 gp120-specific mAb b12 was used as negative control (B). (C) Sur-
face representation of the conserved epitope on HA stem. Colors from gray (not involved) to orange (frequent-
ly contacted) indicate the surface recognized by stem-reactive, broadly neutralizing antibodies. Red indicates 
the location of Trp21. 
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Figure 5. Neutralization of virus attached to cell surface. Diagram (A) represents the experimental setup used 
to test neutralization of virus particles attached to cell surface. The A/Puerto Rico/8/1934 (H1N1) virus has 
been pre-adsorbed on MDCK cells at 4⁰C to avoid virus internalization. Attached viruses were then incubated 
with titrated amounts of HA stem reactive mAbs and residual infectivity was detected. As a control, viruses 
were mock-incubated in cell-free medium before titrated amounts of the mAbs were added. The HIV-1 gp120-
specific mAb b12 was used as non-neutralizing control. 
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Figure 6. Competition with human sera. Competition for neutralization between human sera and HA stem-
reactive mAbs was performed as depicted in diagram (A). A/Puerto Rico/8/1934 (H1N1) virus has been first 
incubated with serum from the indicated donor for 1 h before the indicated mAb was added at a concentration 
of 10 μg/ml. Residual infectivity of the sample was evaluated and compared to infectivity of sample processed 
the same way but without the addition of human serum. Two serum dilutions were chosen: 1st dilution corre-
sponds to a serum concentration giving saturated signals in ELISA while only having minor neutralizing activity 
on the virus. The 2nd (‘neutralizing’) serum concentration is three times higher than the 1st. 
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4.3 Apendix – Immunizations with modified Influenza A 
hemagglutinin proteins induce broadly cross-reactive sera, and 
provide protection against heterologous virus challenge in mice 
This is a short report from the currently ongoing study. I contributed to this project in the 
following way. I designed immunogens used for vaccination, initially tested the efficacy of those 
immunogens in mouse model, developed and tested a large scale system for hemagglutinin 
production, performed the experiment showing that there is no interference between the vaccine-
elicited sera and the stem reactive mAb 1.12. A series of follow-up studies including different 
immunogen designs and various vaccination procedures as well as mouse challenge experiments 
with heterologous virus was performed by Dr. Matteo Bianchi. 
Encouraged by the findings from the phage display selection experiments we decided to use 
the same antigen design to vaccinate mice to elicit antibodies that are cross-reactive with different 
hemagglutinin subtypes, and that may provide protection against a variety of Influenza A isolates. To 
this end, C57BL/6 mice were immunized twice using 35 or 55 μg of the same modified group 1- or 
group 2-derived hemagglutinins, as were used for phage display (i.e. inverted, coupled to magnetic 
beads). We then tested the serum for binding to the same two hemagglutinins in ELISA and found 
that the sera cross-react with both HAs with higher antibody titers seen for the group-2 derived anti-
gen (Figure 1). However, sera from vaccinated mice were not neutralizing the A/Puerto Rico/8/1934 
(H1N1) virus in vitro. As it was later tested, the mouse sera did not compete for the binding to he-
magglutinin with the stem-reactive, heterosubtypic mAb 1.12 suggesting low binding affinities of the 
serum antibodies, or the presence of alternative heterosubtypic but non-neutralizing epitopes. In a 
follow up study performed by Dr. Bianchi it has been shown that sera from vaccinated mice are 
cross-reactive to a broad panel of HA from both phylogenetic groups (H1, H2, H3, H4, H5, H7, H12) 
and that antibody titers can be further increased by introducing adjuvants to the vaccine formula-
tion. Furthermore, it has been proven that the group 1- and 2-derived antigens performed compara-
bly in a non-inverted immobilization whereas omitting the coupling to magnetic beads had a strong 
negative impact on antigen performance. Moreover, although only weak neutralization to a homolo-
gous virus strain could be seen with the mouse sera, mice were protected from a lethal challenge 
with a heterologous viral isolate. The study is currently continued focusing on proving the heterotyp-
ic protection provided by our antigens. 
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Figure 1. Cross-reactivity of mice sera after two IP injections with modified hemagglutinins. The cross-
reactivity has been evaluated in ELISA using recombinant hemagglutinins and strepatavidin (SAV) as indicated 
on graph. 
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5. Discussion 
5.1 Discovery of two new heterosubtypic Influenza A antibodies 
Due to its considerable impact on human health, economics and agriculture, Influenza A virus-
es have been widely studied since their discovery [24, 25, 34]. The major focus of these studies was 
the development of prophylactic and therapeutic agents that could restrict the global spread of sea-
sonal and pandemic viruses. Although much progress was achieved, the highly variable nature of 
Influenza A makes it a constant threat, and requires the development of novel treatment and pre-
vention strategies. In the past 2 decades, a significant effort has been made to engineer drugs and 
vaccines that are effective against a broad range of viruses belonging to multiple subtypes [82, 84, 
93, 94]. The greatest challenge in this approach, however, is the selection of a proper viral compo-
nent that could be exploited as target for prevention and therapy. The primary requirement for such 
component is that it represents a highly conserved structure that can be readily accessed by newly 
designed drugs, or that it possesses a high immunogenicity, in case of novel vaccine formulations. 
Both, immunogenicity and accessibility of hemagglutinin (HA), the major surface antigen of Influenza 
A virus, make it a very suitable research target. However, for a long time it has not been known 
whether HA contains conserved epitopes that are shared between all subtypes and that would be 
useful for the design of novel immunogens. In 1993, a murine antibody, clone c179, has been de-
scribed to neutralize viruses belonging to several HA subtypes from the phylogenetic group 1, and 
this antibody provided the first indication that the epitope recognized by mAb c179 is a part of HA 
stem and is actually conserved [68]. In the last four years, several human heterotypic antibodies 
binding to HA stem have been reported and the existence of hemagglutinin epitopes with a high level 
of conservation, accessibility and immunogenicity confirmed [48, 51, 58, 75, 78, 79, 129]. Notewor-
thy, two of these mAbs, FI6 and CR9114, showed cross-reactivity to multiple virus subtypes from 
both phylogenetic groups, protected from lethal challenge in vivo and also displayed in vitro neutrali-
zation. 
 At the start of the present study, only little was known about heterosubtypic epitopes, and it 
was the goal to broaden this knowledge. Moreover, it was planned to apply my findings in the design 
of a universal Influenza A vaccine candidate. Thus, I developed novel antigens and confirmed the 
integrity of their conserved epitopes by isolation and characterization of naturally occurring antibod-
ies that can bind to these antigens. To this end, I have used phage display to enrich and isolate anti-
bodies that originally were elicited by natural infection or vaccination. The design of these antigens 
took several considerations into account: First, they were based on recombinant full-length hemag-
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glutinin proteins since previous attempts using truncated ‘headless’ HA proteins have failed [117, 
121]. Second, to avoid enrichment of normal strain-specific antibodies, the design of the antigens 
was based on non-human or extinct HA subtypes, implying that all antibodies binding to these anti-
gens are bona fide heterosubtypic [119]. Last, the antigens were designed in a way that access to the 
highly immunogenic and variable HA head was sterically blocked and that the conserved stem was 
prominently exposed. 
The phage display enrichment experiment indicated that my design considerations, and their 
implementation indeed worked out very well. One selection event was sufficient to capture two sets 
of clones presenting two different binding specificities. Out of these I have chosen one representa-
tive for each set (clone 1.12 and 3.1) and further characterized them in multiple assays. To my sur-
prise, mAb 1.12 neutralized multiple isolates belonging to 15 out of 17 existing HA subtypes, confirm-
ing the highly conserved nature of the epitope recognized by this antibody. Moreover, the panel of 
neutralized viruses was isolated over the last 80 years, further supporting the highly conserved na-
ture of the epitope recognized by clone 1.12. Of note, mAb 1.12 was not effective in neutralization of 
A/Shorebird/Delaware/172/2006 (H16N3). This can be partially explained by the fact that the H16 
subtype circulates only in wild birds and therefore phage display library based on human B cell reper-
toire would not contain an antibody capable of recognizing H16 hemagglutinin. In contrast, the sec-
ond isolated clone, mAb 3.1, potently neutralized only subtypes from phylogenetic group 1 (H1, H2, 
H5, H6). As expected, several epitopes mapping experiments, including solving the crystal structure 
for mAb 3.1 in complex with H1 from A/South Carolina/1918 (H1N1), revealed that both antibodies 
bind to the HA stem. Moreover, IgG1 1.12 and 3.1 provided protection to mice challenged with a le-
thal dose of a heterologous H1N1 virus. Thus, these data show that my antibodies are very similar to 
the recently described heterosubtypic mAbs. Taken together, all these findings indicate the presence 
of highly conserved, protective, immunogenic structures in the hemagglutinin stem that could be 
utilized for the design of a universal drug or vaccine against a broad range of Influenza A viruses. 
Interestingly, amongst heterosubtypic, HA-reactive antibodies isolated to date, heavy chains 
encoded by either the VH 1-69 or VH 3-30 germline family are overrepresented [48, 51, 58, 75, 78, 
79, 129]. The heavy chains of mAbs 1.12, F10, CR6261 are representatives of VH 1-69 germline en-
coded antibodies which have also been reported to encode for some broadly cross-reactive HIV 
gp120 mAbs. An interesting feature of the VH 1-69 is the presence of conserved, hydrophobic resi-
dues that are crucial for engaging with HA and gp120 at the tip of HCDR2 [72]. Thus, based on several 
studies the VH 1-69 germline has been proposed to have evolved towards recognition of hydrophobic 
patches present on various viral antigens. In fact, it has been shown that Ig molecules containing the 
VH 1-69 germline sequence, when expressed as B cell receptor on the surface of B cells, initiate the B 
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cell receptor signal cascade following binding of hemagglutinins. Further, only a low number of so-
matic mutations in the VH 1-69 gene are sufficient to generate heterotypic antibodies potently neu-
tralizing Influenza A viruses. In contrast, the extend to which a VH 3-30 gene has to be hypermutated 
to be able to potently block different virus subtypes depends on antibody. For instance, clone 3.1 
carries a low number of hypermutations in its HC and it utilizes almost exclusively its heavy chain for 
binding. In contrast, mAb FI6 is heavily hypermutated in its heavy chain and also uses its light chain 
for binding to hemagglutinin [75]. Based on the limited set of data collected for FI6 and 3.1 it may be 
speculated that the neutralizing breadth of VH 3-30 antibodies is proportional to the amount of in-
troduced hypermutations. 
5.2 Design of universal Influenza A vaccine 
The ultimate goal of this study was to design an immunogen that could provide protection 
against challenge with different virus subtypes, and that could later be developed into a universal 
Influenza A vaccine. As outlined above, the probably most promising approach is to use modified 
hemagglutinin constructs for immunization. Work in this field has been especially boosted in the last 
4 years due to the discovery of numerous broadly cross-reactive antibodies and the molecular char-
acterization of their highly conserved epitopes on HA. Various artificial immunogens that were sup-
posed to display such epitopes have been developed [93, 117, 119-121, 130]. Unfortunately, to date 
only moderate success has been reported. These immunogens only triggered limited cross-reactivity 
and failed to induce neutralizing antibodies. Poor in vivo protection was the major problem when 
using recombinant hemagglutinins in vaccine formulations. Thus, as outlined above, for my study I 
decided to pursue a different approach for the design of hemagglutinin-based immunogens. I took 
advantage of the same set of two antigens that performed remarkably well in phage display selection 
yielding heterotypic antibodies. Due to their covalent up-side-down tethering to beads, access to the 
variable head is blocked, and the conserved stem is prominently exposed. Moreover, due this formu-
lation of the antigen, also a rigid and repetitive antigen pattern that has been shown to favor B cells 
responses is provided [131, 132]. Indeed, when mice were vaccinated with either immunogen, they 
developed high titers of serum antibodies that were cross-reactive to all hemagglutinin subtypes 
tested so far (H1, H2, H3, H4, H5, H7, H12). Although the elicited sera exhibited week neutralization 
only towards the homologous vaccine strain, immunized mice were protected from lethal challenge 
with a heterologous H1N1 virus. Similar in vivo protection by non-neutralizing antibodies has been 
previously reported in several studies, and it is assumed that it is mediated by neutralization-
independent antibody effector functions such as complement activation and antibody-dependent 
cellular cytotoxicity [75, 110, 111]. From competition ELISA experiments we know that the mouse 
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serum antibodies do not compete with mAb 1.12. This suggests that the majority of induced antibod-
ies bind outside the epitope recognized by clone 1.12. I therefore postulate the existence of one or 
several other, conserved, non-neutralizing epitopes on the surface of hemagglutinin. Alternatively, 
the remarkable breadth of the elicited antibodies comes at the price of a poor affinity/off-rate that is 
not able to compete with the monoclonal antibody for binding. Additional animal studies are being 
currently performed to evaluate the potency of our immunogen against challenge with other viral 
strains. Moreover, detailed epitope mapping is being applied to better understand which surface 
areas of our immunogens are inducing antibodies present in sera of vaccinated mice. 
Although both immunogens used in our study performed well in capturing or eliciting cross-
reactive antibodies, I can not state which of the design features is responsible for their high efficacy. 
The HA subtype seems to play a role, as in phage display selection the breadth of antibodies selected 
with the phylogenetic group 2-based antigen was greater than the one based on phylogenetic group 
1. On the other hand both HA constructs performed comparably well in terms of eliciting high titers 
of cross-reactive sera in animal study. Similarly, utilizing the ‘inverted’ group 2-based construct with 
blocked access to HA head in phage display gave better results than in case of a ‘non-inverted’ ver-
sion of the protein whereas no significant differences were seen for both immunogens in animal 
study. However, much higher titers of antibodies were induced by the construct when the protein 
was coupled to magnetic beads compared to immunization with soluble protein. This would indicate 
that either the beads themselves support the antibody production or the better humoral response is 
an effect of accumulating multiple HA molecules in an organized fashion on readily accessible sur-
face. Since mixing beads with uncoupled antigen did not improve the immune response in prelimi-
nary experiments, it can be concluded that the coupling is indeed a considerable factor for the good 
immunogenicity of our immunogen. 
5.3 Comparison of heterosubtypic antibodies binding to Influenza A 
hemagglutinin 
5.3.1  Recognition of the conserved hemagglutinin epitope 
To date, all heterotypic Influenza A antibodies, besides clone CR8020, were reported to recog-
nize almost the same epitope on the stem of hemagglutinin [48, 51, 58, 71, 75, 78, 79]. This epitope 
consists of a hydrophobic grove that is formed by residues 18-52 and 290-330 in HA1 combined with 
aa 1-21 and 38-60 in HA2, and that shows a high degree of conservation within and between sub-
types. Nevertheless, slight structural differences between clades and phylogenetic groups are pre-
sent in this portion of HA, and these result in a various cross-reactivity pattern of heterotypic mAbs. 
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The primary differences comprise an altered orientation of Trp21 in HA2 (Trp212), the presence or 
absence of glycan at position 38 in HA1 as well as different residues at positions 492 and 1112. Some 
of the antibodies like FI6 and CR9114 can overcome these limitations by employing highly flexible 
binding loops and by being able to displace the sugar side chains upon binding [75, 79]. Other anti-
bodies such as CR6261, F10, and 3.1 fail to do so, which probably limits their breadth.  
Interestingly, most antibodies use two types of heavy chains derived either from the germline 
VH 1-69 or VH 3-30. Moreover, recognition of residues in HA hydrophobic groove may be mediated by 
both heavy (HC) and light chain (LC) or exclusively by heavy chain with no specific pattern seen here. 
For example the antibodies 3.1 and FI6 utilize their both chains (3.1 uses the LC to a much lesser ex-
tend) but still present a very distinct cross-reactivity. However, some clear differences are seen for 
these closely related clones that account for their distinct breadth. First, clone 3.1 mainly uses hy-
drophobic residues from the HCDR1 and HCDR3 loops to contact the hydrophobic groove whereas 
FI6 almost exclusively interacts with its very long HCDR3. It seems that such HCDR3 has a significantly 
higher flexibility that allows the Phe residue at its tip to adopt different orientations for the crucial 
interaction with Trp212. A similar increased flexibility has also been reported for HCDR2 of the pan 
Influenza A and B antibody CR9114. In contrast the HC of clone 3.1 contains shorter CDR loops and is 
only moderately mutated comparing to the heavily hypermutated HC of FI6 that contains an addition 
of large amount of N-nucleotides. Thus, based on data summarized from our and previous studies, I 
can state that extensive hypermuation in the heavy chain can generate binding loops that are capa-
ble of recognizing a broader range of HA subtypes  
Interestingly, both germline genes do not require hypermutation to bind or engage HA mole-
cules [72, 75]. Furthermore, these germline genes have also been found in cross-reactive mAbs rec-
ognizing other viral antigens such as HIV, HCMV or SARS. Therefore, we believe that these two par-
ticular Ig germline families evolved to bind conserved elements on multiple viral glycoproteins at 
poor affinities, and that their specificity can then be further shaped by hypermutation into more 
affine antibodies with antiviral activity. Thereby, introduction of mainly hydrophobic residues in a 
proper context of HCDR binding loops may be crucial to recognize different viral antigens. 
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5.3.2 Kinetics of neutralization 
A wide range of heterosubtypic, neutralizing antibodies (nAbs) recognizing Influenza A hemag-
glutinin has been described in detail. Up till now, research in this field was mainly focused on the 
molecular characterization of the recognized epitope, and to some extent also on unraveling the 
mechanism by which HA-reactive nAbs abolish viral infectivity (either by preventing the HA-driven 
membrane fusion or by blocking the HA receptor binding site) [67, 129]. However, neutralization 
kinetics of these nAbs still remains elusive. I therefore decided to use my new heterosubtypic anti-
bodies in combination with the pan Influenza A mAb FI6 to evaluate their mode of action in detail. To 
this end, I developed several different experimental in vitro setups that to some extend mimic crucial 
steps during natural infection. I reasoned that this type of data is essential to understand whether 
heterosubtypic antibodies binding to a membrane-proximal epitope would be effective for treatment 
and prevention of influenza A infections in humans, in particular if they are elicited by a future uni-
versal influenza vaccine. In the first of my experiments we asked if virus neutralization with HA stem-
reactive antibodies is reversible. Such studies were previously performed for broadly reactive HIV-1 
gp120-specific mAbs showing that some of them irreversibly neutralize viral infectivity [133]. Surpris-
ingly, in my assay all antibodies from the test panel provided complete and irreversible neutralization 
of an H1N1 virus. At this point I do not know the exact mechanism behind this irreversibility. It is 
likely that those antibodies bind HA molecules with very low overall dissociation rates and thus keep 
the virus particles non-infective over a prolonged period of time. This would be in agreement with 
the measured high binding affinities for these antibodies. Fab fragments of these mAbs bind various 
hemagglutinins with KD values in nanomolar range and even higher avidities can be expected for the 
corresponding IgG molecule. Taking into account the high density of HA spikes on the virus’ surface 
Figure 13. The conserved hemagglutinin epitope. Surface repre-
sentation of the conserved epitope on HA stem. Colors from gray 
(not involved) to orange (frequently contacted) indicate the 
surface recognized by stem-reactive, broadly neutralizing anti-
bodies. Red indicates the location of Trp21. Adapted from Lars 
Hangartner. Figure was prepared using PyMOL software (DaLano 
Scientific LLC). 
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in combination with the high interaction affinities, I suspect that it would be difficult for HA-stem 
reactive antibodies to completely dissociate from the virus particle once they are bound to hemag-
glutinin. However, as revealed in my second experiment, complete neutralization can only be 
achieved if the mAbs bind to virus particles in solution. Once bound to the cell surface, I found that 
neutralization of viral infectivity required much higher antibody concentrations. I assume that HA 
spikes are occluded in the virological synapse (formed after the virus attaches to cellular membrane 
receptors) and are therefore more difficult to access for the mAbs. Nevertheless, based on the suc-
cessful animal protection study I conclude that this limited neutralization of bound virus does not 
have a signifficant impact on protection, presumably because in mice, this shortcoming is compen-
sated by the non-neutralizing effector functions of the transferred antibodies. 
Since most humans display various amounts of homotypic antibodies induced by infection and 
vaccination, and since these antibodies are binding to apical epitopes, it was speculated that their 
binding would impair access of heterosubtypic mAbs to their membrane-proximal epitopes. Such 
interference by homotypic antibodies would have a great impact on the success of any therapeutic or 
preventive use of heterosubtypic antibodies. However, I could show that the presence of strain-
specific human serum antibodies does not impact the neutralization activity of mAbs 1.12, 3.1 and 
FI6. Thus, my data suggest that from the mechanistic point of view, antibodies recognizing conserved 
epitopes on hemagglutinin stem would be effective as treatment option and when induced by a uni-
versal Influenza A vaccine. 
The discovery of a novel heterosubtypic Influenza A antibodies altogether with a detailed eval-
uation of binding mechanism of these mAbs provides further insight into the subject of conserved 
epitopes present on hemagglutinin. The data collected may be essential for the design of a new im-
munogen. Moreover, these data justify the use of hemagglutinin as antigen capable of inducing het-
erosubtypic humoral response. Based on the knowledge and experience collected in our study we 
have prepared a set of vaccine candidates that performed surprisingly well in animal experiments. 
We are further evaluating and optimizing these designed immunogens aiming at development of a 
universal influenza vaccine. 
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